<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01181323</url>
  </required_header>
  <id_info>
    <org_study_id>09-0007</org_study_id>
    <secondary_id>HHSN272200800006C</secondary_id>
    <nct_id>NCT01181323</nct_id>
  </id_info>
  <brief_title>Post-Partum Immunization With Live Attenuated Influenza Vaccine (LAIV) or Trivalent Influenza Vaccine (TIV) in Post-Partum Breast Feeding Women</brief_title>
  <official_title>A Randomized, Double-Blind Trial, Comparing the Safety in Mothers and Their Infants and Immunogenicity in Mothers of Live Attenuated Influenza Vaccine (LAIV) to Inactivated Trivalent Influenza Vaccine (TIV) When Administered to Breast Feeding Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <brief_summary>
    <textblock>
      The purpose of this research study is to learn more about the safety of 2 licensed flu
      vaccines, nasal spray and flu vaccine shot, in mothers and their infants, when given to women
      who are breastfeeding and to compare the immune response (body's defense against foreign
      substances) of breastfeeding mothers, who receive intranasal flu vaccine, with breastfeeding
      mothers receiving the flu vaccine shot. Healthy women (240 volunteers, 28-120 days post
      delivery) who plan to breastfeed through 28 days post vaccination and who have not received
      influenza vaccine for the influenza season for which they are being enrolled, will be
      assigned by chance to 1 of the 2 vaccines in the following manner: flu vaccine nasal spray
      and a placebo (inactive substance) shot or a flu vaccine shot and a placebo nasal spray.
      Study procedures include: nasal swabs, blood samples, and completion of memory aids.
      Participants will be involved in this United States based study for about 6 months.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Due to limited data available on the safety and immune response to live attenuated influenza
      vaccine (LAIV) in breast-feeding women and the lack of information on the induction of
      immunoglobulin (Ig) A and IgG against influenza virus in breast milk, this study compares the
      safety in mothers and their infants and immunogenicity in mothers of standard dose
      inactivated trivalent influenza vaccine (TIV) and LAIV when administered between 28-120 days
      of delivery in breastfeeding women. This is a multi-site, randomized, double-blinded trial in
      240 post-partum breastfeeding women, 18-49 years of age and their infants. Once enrolled, a
      blood sample and a breast milk sample will be collected. Nasal swabs will be obtained and
      targeted physical examinations (TPE) will be conducted from mother and infant, if indicated.
      Each subject will receive either a single intramuscular (IM) 0.5 milliliter (mL) dose of TIV
      and 0.2 mL of placebo administered intranasally, or 0.2 mL intranasal dose of LAIV and 0.5 mL
      of placebo administered IM. All subjects will maintain a memory aid recording oral
      temperature, and systemic and local adverse events (AEs) for 8 days after study products have
      been administered. Approximately day 2 and 8 all subjects will return to the clinic for
      collection of breast milk samples and nasal swabs (mother and infant) and the memory aid will
      be reviewed. Approximately Day 28 after vaccination, all subjects will return to the clinic
      for breast milk and a blood sampling. During the time between vaccination and the day 28
      visit, if mother or infant has an influenza-like illness (ILI), a clinic visit may be
      required within 72 hours of illness onset. The clinic visit will be required for any illness
      that meets the Centers for Disease Control and Prevention's definition of an ILI for the
      mother. Investigator discretion will discern if an illness in the infant requires an ILI
      visit. Any respiratory or gastrointestinal (GI) serious adverse event (SAE) in the infant
      will also require a clinic visit. If the mother has an ILI, nasal swabs will be collected on
      her, and samples from the infant (if possible). If the infant has an ILI, nasal swabs will be
      collected on both the mother and infant. At approximately Day 42 after vaccination, all
      subjects will have a phone call for assessment of any medically attended GI or respiratory
      illness in the infant from Day 29-42. Approximately 6 months after vaccination all subjects
      will have a phone call for assessment of any SAEs in the subject or the infant since Day 42.
      SAE data and new onset chronic medical conditions in the mother will be collected from Day
      0-180. At all study visits, subjects will be asked about acute, temporary breast diseases
      (mastitis, abscesses) and any changes in breastfeeding, i.e., interruption and if so, how
      long (in weeks). Subjects will report information on current breast milk consumption by
      infant. Unsolicited non-serious AE data will be captured Day 0-28. Respiratory and GI AEs
      will be captured for the infant from Day 28-42. SAE data will be captured from Day 0-180 for
      both mother and infant. Blood samples will be tested for hemagglutination inhibition (HAI),
      IgG, and IgA as measured by enzyme linked-immunosorbent assay (ELISA). Breast milk samples
      will be assayed for IgA and IgG antibodies by ELISA. Breast milk and nasal swabs will also be
      tested for LAIV. Parent protocol to sub-study 11-0048.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Actual">May 2013</completion_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Reporting Serious Adverse Events (SAEs)</measure>
    <time_frame>Day 0 to Day 180 post vaccination</time_frame>
    <description>Serious adverse events included any untoward medical occurrence that resulted in death; was life threatening; was a persistent/significant disability/incapacity; required inpatient hospitalization or prolongation thereof; was a congenital anomaly/birth defect; or may have jeopardized the participant, or required intervention to prevent one of the outcomes, regardless of relationship to study product or study participation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Reporting New Onset Chronic Medical Conditions</measure>
    <time_frame>Day 0 to Day 180 post vaccination</time_frame>
    <description>New onset chronic medical condition was defined as any new ICD-10 diagnosis for a participant that was expected to continue for at least 6 months and require continued health care intervention. ICD-10 = International Statistical Classification of Diseases and Related Health Problems, 10th revision. Maternal participants were asked at each visit through 180 days after enrollment if they or their infants had any new diagnosis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Infant Participants Reporting Solicited Systemic Adverse Events Within 11 Days of Maternal Vaccination</measure>
    <time_frame>Day 0 to Day 10 post vaccination</time_frame>
    <description>Maternal participants maintained a memory aid to record daily the occurrence in their infants of systemic adverse events of fever (defined as rectal temperature 37.8 degrees Celsius or greater), drowsiness, irritability/fussiness, loss of appetite, nasal congestion, difficulty breathing, runny nose, and cough for 11 days (Day 0-10) after maternal vaccination based on protocol-defined grading (none, mild, moderate or severe) for each symptom. Rectal temperature was measured once daily. Participants are counted if they were reported as experiencing the symptom at any severity on any of the 11 days.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participating Reporting Non-serious Unsolicited Adverse Events Related to Vaccination Within 28 Days of Maternal Vaccination</measure>
    <time_frame>Day 0 to Day 28 post vaccination</time_frame>
    <description>Adverse events (AE) for this protocol used the International Conference on Harmonization (ICH) guideline E6 definition of AE, any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product regardless of its causal relationship to the study treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of investigational product. Related was defined as a reasonable possibility that the study product caused the AE. Reasonable possibility means that there is evidence to suggest a causal relationship between the study product and the adverse event. Non-serious AEs were those that did not meet the definition of serious (see Outcome Measure 1). Maternal participants were queried at each visit through 28 days after vaccination for the occurrence of any AE for her or the infant separately from the pre-defined solicited symptoms.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Breast Milk ELISA IgA and IgG Geometric Mean Titers (GMT) to Each of the Vaccine Influenza Strains</measure>
    <time_frame>Day 0 and 28 post vaccination</time_frame>
    <description>Breast milk was collected at Day 0 prior to vaccination and again at 28 days following vaccination for testing in IgA and IgG ELISA Assays. The ELISA assay was conducted with the antigens in the 2011-2012 seasonal influenza vaccine, A/Perth/16/2009 (H3N2) and B/Brisbane/60/2008, those in the 2012-2013 seasonal influenza vaccine, A/Victoria/361/2011 and B/Wisconsin/1/2010, and the antigen in both seasons's vaccine, A/California/7/2009 (H1N1). The lower limit of detection is 5.82 units/mL for IgA and 2.56 units/mL for IgG. Titers below the limit of detection were reported as one-half the limit of detection.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Infant Participants With Medically Attended Respiratory or Gastrointestinal AEs 28-42 Days After Maternal Vaccination</measure>
    <time_frame>Within 28-42 days after maternal vaccination</time_frame>
    <description>Maternal participants were contacted by telephone at Day 42 to report all medically attended respiratory or gastrointestinal adverse events occurring in the infant participants between 28 and 42 days after maternal vaccination.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Maternal Participants Reporting Fever After Vaccination</measure>
    <time_frame>Day 0-7 post vaccination</time_frame>
    <description>Participants were provided with a thermometer and a memory aid on which to record daily oral temperatures for 8 days after vaccination (Day 0-7). The protocol defined fever as oral temperature of 37.8 degrees Celsius or higher. Participants are counted as experiencing fever if they reported oral temperatures of 37.8 degrees Celsius or higher on any of the 8 days.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Maternal Participants Reporting Solicited Subjective Systemic Symptoms After Vaccination</measure>
    <time_frame>Day 0-7 post vaccination</time_frame>
    <description>Participants maintained a memory aid to record daily the occurrence of systemic symptoms of feverishness, malaise, myalgia, headache, nausea, weakness, and chills for 8 days after vaccination (Day 0-7) based on their interference with daily activities. Participants are counted if they reported experiencing the symptom at any severity on any of the 8 days.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Maternal Participants Reporting Solicited Subjective Local Symptoms After Vaccination</measure>
    <time_frame>Day 0-7 post vaccination</time_frame>
    <description>Participants maintained a memory aid to record daily the occurrence of local symptoms of nasal congestion, runny nose, cough, sore throat, nasal bleeding, pain at injection site, tenderness at injection site, and swelling at injection site for 8 days after vaccination (Day 0-7) based on their interference with daily activities. Participants are counted if they reported experiencing the symptom at any severity on any of the 8 days.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Maternal Participants Reporting Solicited Quantitative Local Symptoms After Vaccination</measure>
    <time_frame>Day 0-7 post vaccination</time_frame>
    <description>Participants maintained a memory aid to record daily the occurrence of local reactions of redness and swelling for 8 days after vaccination (Day 0-7). If the reaction was present, the maximum diameter was measured in millimeters (mm). Participants are counted if they reported experiencing the reaction with any measurement greater than 0 mm on any of the 8 days.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Titers (GMT) in Maternal Sera of Hemagglutination Inhibition (HAI) Antibodies to Each of the Influenza Strains in the Vaccine Received</measure>
    <time_frame>Day 0 and 28 post vaccination</time_frame>
    <description>Blood was collected for HAI assay at Day 0 prior to vaccination and again at 28 days following vaccination. The HAI assay was conducted with the antigens in the 2011-2012 seasonal influenza vaccine, A/Perth/16/2009 (H3N2) and B/Brisbane/60/2008, those in the 2012-2013 seasonal influenza vaccine, A/Victoria/361/2011 and B/Wisconsin/1/2010, and the antigen in both seasons's vaccine, A/California/7/2009 (H1N1). The lower limit of detection for the assay was a titer of 10, sera samples below detection were given a value of 5 for analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Maternal Participants With Season-specific LAIV Influenza A and B Strains Detected in Respiratory Secretions Prior to Vaccination.</measure>
    <time_frame>Day 0 prior to vaccination</time_frame>
    <description>Nasal swab samples were collected from all maternal participants prior to vaccination for PCR and cell culture to assess for the presence of the viruses in the LAIV vaccine in respiratory secretions. The data coordinating center selected 25% of participants in the TIV group for testing to serve as an internal control for the assay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Maternal Participants With Season-specific LAIV Influenza A and B Strains Detected in Respiratory Secretions at Day 2 Post Vaccination.</measure>
    <time_frame>Day 2 post vaccination</time_frame>
    <description>Nasal swab samples were collected from all maternal participants at Day 2 post vaccination for PCR and cell culture to assess for the presence of the viruses in the LAIV vaccine in respiratory secretions. The data coordinating center selected 25% of participants in the TIV group for testing to serve as an internal control for the assay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Maternal Participants With Season-specific LAIV Influenza A and B Strains Detected in Respiratory Secretions at Day 8 Post Vaccination.</measure>
    <time_frame>Day 8 post vaccination</time_frame>
    <description>Nasal swab samples were collected from all maternal participants at Day 8 post vaccination for PCR and cell culture to assess for the presence of the viruses in the LAIV vaccine in respiratory secretions. The data coordinating center selected 25% of participants in the TIV group for testing to serve as an internal control for the assay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Infant Participants With Season-specific LAIV Influenza A and B Strains Detected in Respiratory Secretions Prior to Vaccination.</measure>
    <time_frame>Day 0 prior to vaccination</time_frame>
    <description>Nasal swab samples were collected from all infant participants prior to vaccination for PCR and cell culture to assess for the presence of the viruses in the LAIV vaccine in respiratory secretions. The data coordinating center selected 25% of participants in the TIV group for testing to serve as an internal control for the assay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Infant Participants With Season-specific LAIV Influenza A and B Strains Detected in Respiratory Secretions at Day 2 Post Vaccination.</measure>
    <time_frame>Day 2 post vaccination</time_frame>
    <description>Nasal swab samples were collected from all infant participants at Day 2 post vaccination for PCR and cell culture to assess for the presence of the viruses in the LAIV vaccine in respiratory secretions. The data coordinating center selected 25% of participants in the TIV group for testing to serve as an internal control for the assay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Infant Participants With Season-specific LAIV Influenza A and B Strains Detected in Respiratory Secretions at Day 8 Post Vaccination.</measure>
    <time_frame>Day 8 post vaccination</time_frame>
    <description>Nasal swab samples were collected from all infant participants at Day 8 post vaccination for PCR and cell culture to assess for the presence of the viruses in the LAIV vaccine in respiratory secretions. The data coordinating center selected 25% of participants in the TIV group for testing to serve as an internal control for the assay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Maternal Participants Positive for the Season-specific LAIV Influenza A Strain in Respiratory Secretions at Day 0 Who Were Positive for H1N1 and/or H3N2 Strains.</measure>
    <time_frame>Day 0 prior to vaccination</time_frame>
    <description>Nasal swab samples were collected from all maternal participants prior to vaccination for PCR and cell culture to assess for the presence of the viruses in the LAIV vaccine in respiratory secretions. Those who were positive for the Influenza A strain were further tested to identify the H1N1 and H3N2 strain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Maternal and Infant Participants Positive for the Season-specific LAIV Influenza A Strain in Respiratory Secretions at Day 2 Who Were Positive for H1N1 and/or H3N2 Strains.</measure>
    <time_frame>Day 2 post vaccination</time_frame>
    <description>Nasal swab samples were collected from all maternal and infant participants at Day 2 post vaccination for PCR and cell culture to assess for the presence of the viruses in the LAIV vaccine in respiratory secretions. Those who were positive for the Influenza A strain were further tested to identify the H1N1 and H3N2 strain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Maternal Participants Positive for the Season-specific LAIV Influenza A Strain in Respiratory Secretions at Day 8 Who Were Positive for H1N1 and/or H3N2 Strains.</measure>
    <time_frame>Day 8 post vaccination</time_frame>
    <description>Nasal swab samples were collected from all maternal participants at Day 8 post vaccination for PCR and cell culture to assess for the presence of the viruses in the LAIV vaccine in respiratory secretions. Those who were positive for the Influenza A strain were further tested to identify the H1N1 and H3N2 strain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Maternal Participants With Season-specific LAIV Influenza A and B Strains Detected in Breast Milk Following Vaccination.</measure>
    <time_frame>Day 2 and 8 post vaccination</time_frame>
    <description>Breast milk was collected from all maternal participants prior at Days 2 and 8 post vaccination for PCR and cell culture to assess for the presence of the viruses in the LAIV vaccine. The data coordinating center selected 25% of participants in the TIV group for testing to serve as an internal control for the assay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ELISA IgA and IgG GMT to Each of the Influenza Strains in the Vaccine Received in Sera of Maternal Subjects</measure>
    <time_frame>Day 0 and Day 28 post vaccination</time_frame>
    <description>Blood was collected from maternal subjects on Day 0 prior to vaccination, and at Day 28 post vaccination for assessment of IgA and IgG antibodies with a standard ELISA assay. The ELISA assay was conducted with the antigens in the 2011-2012 seasonal influenza vaccine, A/Perth/16/2009 (H3N2) and B/Brisbane/60/2008, those in the 2012-2013 seasonal influenza vaccine, A/Victoria/361/2011 and B/Wisconsin/1/2010, and the antigen in both seasons' vaccines, A/California/7/2009 (H1N1). The lower limit of detection is 5.82 units/mL for IgA and 2.56 units/mL for IgG. Titers below the limit of detection were reported as one-half the limit of detection.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">240</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>Group 1: LAIV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.2 ml of Live attenuated influenza vaccine (LAIV), Flumist® given intranasally (IN) and 0.5 ml of placebo given intramuscularly (IM) injection administered to 120 maternal subjects.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2: TIV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.5 ml of Inactivated Trivalent Influenza Vaccine (TIV), Fluzone® given intramuscularly (IM) and 0.2 ml of placebo given intranasally (IN) administered to 120 maternal subjects.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>0.2 ml of Intranasal placebo study product (using sucrose phosphate placebo filled sprayers), will be administered to maternal subjects.</description>
    <arm_group_label>Group 2: TIV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Cold-adapted live attenuated influenza virus vaccine, trivalent</intervention_name>
    <description>Licensed product formulated for the 2011-2012 or 2012-2013 influenza season. Standard dose LAIV (Flumist®) 0.1 ml administered to maternal subjects intranasally in each nostril for a total of 0.2 mL.</description>
    <arm_group_label>Group 1: LAIV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>0.5 ml of Sterile saline (0.9 percent Sodium Chloride for injection), administered IM to maternal subjects.</description>
    <arm_group_label>Group 1: LAIV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Trivalent inactivated influenza vaccine</intervention_name>
    <description>Preservative free, licensed product formulated for the 2011-2012 or 2012-2013 influenza season. Standard dose of TIV (Fluzone®) 0.5 ml administered to maternal subjects, IM in the deltoid.</description>
    <arm_group_label>Group 2: TIV</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Maternal Subject

          -  Women age 18-49 years of age (inclusive) within 28-120 days of delivery.

          -  Is in good health, as determined by vital signs (heart rate &lt;/=100 beats per minute
             (bpm); blood pressure: systolic &lt;150 mm Hg; diastolic &lt;90 mm Hg; oral temperature
             &lt;100.0 degrees Fahrenheit), medical history and a targeted physical examination if
             indicated based on medical history.

          -  Willing and capable of providing written informed consent for herself and infant.

          -  Available for entire study duration, clinic visits and phone calls.

          -  Planning on breast feeding from time of vaccination through 28 days post-vaccination.
             Breast milk must be at least one half of the source of the infant's feeding.

          -  Willing to practice adequate contraception for at least 28 days after receipt of study
             vaccine if not surgically sterile via post-partum tubal ligation, bilateral
             oophorectomy or hysterectomy. Adequate contraception may include, but is not limited
             to, abstinence, monogamous relationship with a vasectomized partner, barrier methods
             such as condoms or diaphragms with spermicides, or licensed hormonal methods that are
             compatible with breastfeeding an infant.

          -  May be reached by any IRB-approved form of communication during study period. May
             include telephone, email, web based, social media, and/or text messaging, based on
             specific local IRB recommendations.

          -  Agree to sign a medical release for herself and her infant (if needed) so that study
             personnel may obtain medical information about her or her infant's health.

        Infant The infant(s) should be in good health as assessed by medical history, interview,
        rectal temperature and a targeted physical examination based on medical history.

          -  Infant born greater than or equal to 36 weeks gestation.

          -  Successful receipt of breast milk for at least two days prior to enrollment. Breast
             milk must be at least one half of the source of feeding, i.e., some supplementation is
             acceptable.

        Exclusion Criteria:

        Maternal Subject

          -  History of receipt of licensed influenza vaccine for the current influenza season. (If
             enrolled in 2011-2012 season [October 2011 - February 2012], subject must not have
             received 2011-2012 influenza vaccine. If enrolled in the 2012-2013 season [July 2012
             or later], subject must not have received 2012-2013 influenza vaccine).

          -  History of previous participation in this study.

          -  Known allergy to eggs, egg proteins or other components in the vaccines (i.e.
             formaldehyde, polyethylene glycol, p-isooctylphenyl ether, sucrose, gelatin,
             polysorbate 80, gentamicin, arginine, sodium phosphate, sodium chloride, octylphenol
             ethoxylate, EDTA).

          -  If enrolled in the 2011-2012 season, known or suspected latex allergy. For the
             2012-2013 season, known or suspected latex allergy is not a reason for exclusion.

          -  History of severe reactions following immunization with contemporary influenza virus
             vaccines.

          -  Received any other licensed vaccines within 14 days (for inactivated vaccines) or 28
             days (for live vaccines) prior to vaccination in this study, or expects to receive a
             licensed vaccine during the 28 days after vaccination in this study.

          -  Received an experimental/investigational agent (vaccine, drug, biologic, device, blood
             product, or medication) within 28 days prior to vaccination in this study, or expects
             to receive an experimental/investigational agent within the study time period (180
             days after vaccination in this study).

          -  Received antiviral agent against influenza A and/or B within 48 hours prior to
             vaccination in this study. Antiviral agents should not be administered until 2 weeks
             after vaccination in this study unless medically necessary.

          -  A moderate to severe acute illness and/or an oral temperature &gt;/= 100.0 F, within 72
             hr prior to vaccination. (This may result in a temporary delay of vaccination).

          -  Immunosuppression as a result of an underlying illness or treatment, or use of
             anti-cancer chemotherapy or radiation therapy within the preceding 36 months.

          -  Active neoplastic disease or a history of any hematologic malignancy (cancers of blood
             or bone marrow) or current bleeding or blood clotting disorder.

          -  Current diagnosis of asthma.

          -  History of asthma, wheezing, or bronchospasm in the last 5 years.

          -  Long term (at least 14 days of prednisone 2 mg/kg or equivalent other glucocorticoid)
             use of oral or parenteral steroids, high-dose inhaled steroids (&gt;800 microgram/day of
             beclomethasone dipropionate or equivalent) within the preceding 6 months (topical
             steroids are allowed).

          -  Use of intranasal steroids within 14 days prior to vaccination in this study or within
             14 days after receipt of study vaccine.

          -  Use of intranasal products within 6 hours prior to vaccination in this study or
             expects to use intranasal products within 6 hours post study vaccination.

          -  History of receiving immunoglobulin or other blood product (with exception of RhoGAM)
             within the 3 months prior to vaccination in this study.

          -  Diagnosis of a current and uncontrolled major psychiatric disorder.

          -  Has been hospitalized within the past 10 years for psychiatric illness, suicide
             attempt, or confinement for danger to self or others.

          -  The subject is receiving listed psychiatric drugs (aripiprazole, clozapine,
             ziprasidone, haloperidol, molindone, loxapine, thioridazine, thiothixene, pimozide,
             fluphenazine, risperidone, mesoridazine, quetiapine, trifluoperazine,
             trifluopromazine, chlorprothixene, chlorpromazine, perphenazine, olanzapine,
             carbamazepine, divalproex sodium, lithium carbonate or lithium citrate). Subjects who
             are receiving a single antidepressant drug and are stable for at least 3 months prior
             to enrollment without decompensating are allowed enrollment into the study.

          -  The subject is receiving medications contraindicated with breast feeding.

          -  Known active human immunodeficiency virus (HIV), hepatitis B, or hepatitis C
             infection.

          -  An active neurological (such as, but not limited to seizure disorder), auto-immune or
             vascular disease.

          -  Active breast infection or breast abscess. (Study vaccination will be delayed until
             this breast infection or breast abscess has been treated and is resolved.)

          -  History of frequent epistaxis (nose bleeds).

          -  History of alcohol or drug abuse in the 1 year prior to enrollment.

          -  History of Guillain-Barré syndrome.

          -  Any known immunocompromised family member/household contact (such as active cancer,
             lupus, inflammatory bowel disease, HIV infection, or receipt of an organ or bone
             marrow transplant).

          -  Has an acute or chronic medical condition that, in the opinion of the investigator
             would interfere with the evaluation of responses (this includes, but is not limited
             to: known chronic liver, lung or heart disease, chronic anemia, metabolic disorders
             such as diabetes (resolved gestational diabetes is acceptable), significant renal
             disease, transplant recipients).

          -  Pregnant or planning to become pregnant during the 28 days after receipt of study
             vaccine.

          -  Has any condition that would, in the opinion of the site investigator, place the
             subject at an unacceptable risk of injury or render the subject unable to meet the
             requirements of the protocol.

        Infant

          -  Major congenital malformations.

          -  Syndromes that affect breastfeeding.

          -  Progressive neurological disease or a history of any seizure.

          -  Chronic lung disease or oxygen requirement for heart disease.

          -  History of bronchopulmonary dysplasia, wheezing, reactive airway disease,
             hospitalization for respiratory illness, or use of bronchodilators.

          -  Any receipt of glucocorticoids.

          -  Immunodeficiency disease or use of immunosuppressive therapy including perinatal
             exposure to or infection with HIV, or known infection with hepatitis B or hepatitis C.

          -  Received an experimental/investigational agent (vaccine, drug, biologic, device, blood
             product, or medication) within 28 days prior to this study, or expects to receive an
             experimental/investigational agent within the study time period (180 days after
             mother's vaccination in this study).

          -  A moderate to severe acute illness and/or a rectal temperature greater than or equal
             to 100.0 F (37.8 C), within 72 hours prior to mother's vaccination (This may result in
             a temporary delay of vaccination in mother).

          -  Received any licensed vaccines within 7 days prior to mother's vaccination in this
             study, or expects to receive a licensed vaccine during the 10 days after mother's
             vaccination in this study (This may result in a temporary delay of vaccination in
             mother).

          -  History of documented laboratory-confirmed influenza infection.

          -  Receipt of blood or blood products.

          -  Have a condition that may place the infant at an unacceptable risk of injury or would
             make it difficult for the infant to meet the requirements of the study.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>49 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Washington Hospital Center - Obstetrics and Gynecology</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010-3017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory Children's Center - Pediatric Infectious Diseases</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322-1014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Louis University - Center for Vaccine Development</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63104-1015</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke Translational Medicine Institute - Clinical Vaccine Unit</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27704-2120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center - Infectious Diseases</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229-3026</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Group Health Research Institute - Seattle</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98101-1466</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 12, 2010</study_first_submitted>
  <study_first_submitted_qc>August 12, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 13, 2010</study_first_posted>
  <results_first_submitted>April 17, 2014</results_first_submitted>
  <results_first_submitted_qc>April 17, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 16, 2014</results_first_posted>
  <last_update_submitted>January 15, 2015</last_update_submitted>
  <last_update_submitted_qc>January 15, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 28, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>influenza, vaccine, breastfeeding, post-partum women, infant, LAIV, TIV, parent protocol</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were healthy post-partum women recruited from existing volunteer populations and from the communities at large around the clinical sites. Participants were enrolled between 6Sep2011 and 31Oct2012</recruitment_details>
      <pre_assignment_details>Maternal participants and their infants were enrolled separately in the study for the purposes of data collection, analysis and reporting. For baseline measures, adverse events, and outcome measures as appropriate, the infants are defined as their own arms of the study based on the study product the mother received.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Maternal LAIV</title>
          <description>Healthy women who planned to breast feed through 28 days post vaccination received 0.2 mL of licensed live attenuated influenza vaccine (LAIV), Flumist®, intranasally, and 0.5 ml of sterile saline placebo by intramuscular injection</description>
        </group>
        <group group_id="P2">
          <title>Maternal TIV</title>
          <description>Healthy women who planned to breast feed for 28 days post vaccination received 0.5 mL licensed seasonal trivalent influenza vaccine (TIV) by intramuscular injection, Fluzone®, by intramuscular injection, and 0.2 mL sucrose phosphate placebo intranasally.</description>
        </group>
        <group group_id="P3">
          <title>Infant LAIV</title>
          <description>Infants of women enrolled to receive LAIV were enrolled separately in the protocol to be followed for safety outcomes.</description>
        </group>
        <group group_id="P4">
          <title>Infant TIV</title>
          <description>Infants of women enrolled to receive TIV were enrolled separately in the protocol to be followed for safety outcomes.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="124"/>
                <participants group_id="P2" count="124"/>
                <participants group_id="P3" count="124"/>
                <participants group_id="P4" count="125"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="123"/>
                <participants group_id="P2" count="121"/>
                <participants group_id="P3" count="123"/>
                <participants group_id="P4" count="122"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All enrolled subjects are included in the baseline analysis population.</population>
      <group_list>
        <group group_id="B1">
          <title>Maternal LAIV</title>
          <description>Healthy women who planned to breast feed through 28 days post vaccination received 0.2 mL of licensed live attenuated influenza vaccine (LAIV), Flumist®, intranasally, and 0.5 ml of sterile saline placebo by intramuscular injection.</description>
        </group>
        <group group_id="B2">
          <title>Maternal TIV</title>
          <description>Healthy women who planned to breast feed for 28 days post vaccination received 0.5 mL licensed seasonal trivalent influenza vaccine (TIV) by intramuscular injection, Fluzone®, by intramuscular injection, and 0.2 mL sucrose phosphate placebo intranasally.</description>
        </group>
        <group group_id="B3">
          <title>Infant LAIV</title>
          <description>Infants of women enrolled to receive LAIV were enrolled separately in the protocol to be followed for safety outcomes.</description>
        </group>
        <group group_id="B4">
          <title>Infant TIV</title>
          <description>Infants of women enrolled to receive TIV were enrolled separately in the protocol to be followed for safety outcomes.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="124"/>
            <count group_id="B2" value="124"/>
            <count group_id="B3" value="124"/>
            <count group_id="B4" value="125"/>
            <count group_id="B5" value="497"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="124"/>
                    <measurement group_id="B4" value="125"/>
                    <measurement group_id="B5" value="249"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="124"/>
                    <measurement group_id="B2" value="124"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="248"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="124"/>
                    <measurement group_id="B2" value="124"/>
                    <measurement group_id="B3" value="61"/>
                    <measurement group_id="B4" value="62"/>
                    <measurement group_id="B5" value="371"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="63"/>
                    <measurement group_id="B4" value="63"/>
                    <measurement group_id="B5" value="126"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="98"/>
                    <measurement group_id="B2" value="98"/>
                    <measurement group_id="B3" value="95"/>
                    <measurement group_id="B4" value="93"/>
                    <measurement group_id="B5" value="384"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="17"/>
                    <measurement group_id="B5" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="118"/>
                    <measurement group_id="B2" value="123"/>
                    <measurement group_id="B3" value="114"/>
                    <measurement group_id="B4" value="119"/>
                    <measurement group_id="B5" value="474"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="124"/>
                    <measurement group_id="B2" value="124"/>
                    <measurement group_id="B3" value="124"/>
                    <measurement group_id="B4" value="125"/>
                    <measurement group_id="B5" value="497"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Reporting Serious Adverse Events (SAEs)</title>
        <description>Serious adverse events included any untoward medical occurrence that resulted in death; was life threatening; was a persistent/significant disability/incapacity; required inpatient hospitalization or prolongation thereof; was a congenital anomaly/birth defect; or may have jeopardized the participant, or required intervention to prevent one of the outcomes, regardless of relationship to study product or study participation.</description>
        <time_frame>Day 0 to Day 180 post vaccination</time_frame>
        <population>All enrolled participants are included in the analysis population for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Maternal LAIV</title>
            <description>Healthy women who planned to breast feed through 28 days post vaccination received 0.2 mL of licensed live attenuated influenza vaccine (LAIV), Flumist®, intranasally, and 0.5 ml of sterile saline placebo by intramuscular injection.</description>
          </group>
          <group group_id="O2">
            <title>Maternal TIV</title>
            <description>Healthy women who planned to breast feed for 28 days post vaccination received 0.5 mL licensed seasonal trivalent influenza vaccine (TIV) by intramuscular injection, Fluzone®, by intramuscular injection, and 0.2 mL sucrose phosphate placebo intranasally.</description>
          </group>
          <group group_id="O3">
            <title>Infant LAIV</title>
            <description>Infants of women enrolled to receive LAIV were enrolled separately in the protocol to be followed for safety outcomes.</description>
          </group>
          <group group_id="O4">
            <title>Infant TIV</title>
            <description>Infants of women enrolled to receive TIV were enrolled separately in the protocol to be followed for safety outcomes.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Reporting Serious Adverse Events (SAEs)</title>
          <description>Serious adverse events included any untoward medical occurrence that resulted in death; was life threatening; was a persistent/significant disability/incapacity; required inpatient hospitalization or prolongation thereof; was a congenital anomaly/birth defect; or may have jeopardized the participant, or required intervention to prevent one of the outcomes, regardless of relationship to study product or study participation.</description>
          <population>All enrolled participants are included in the analysis population for this outcome measure.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="124"/>
                <count group_id="O2" value="124"/>
                <count group_id="O3" value="124"/>
                <count group_id="O4" value="125"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Reporting New Onset Chronic Medical Conditions</title>
        <description>New onset chronic medical condition was defined as any new ICD-10 diagnosis for a participant that was expected to continue for at least 6 months and require continued health care intervention. ICD-10 = International Statistical Classification of Diseases and Related Health Problems, 10th revision. Maternal participants were asked at each visit through 180 days after enrollment if they or their infants had any new diagnosis.</description>
        <time_frame>Day 0 to Day 180 post vaccination</time_frame>
        <population>All enrolled participants are included in the analysis population for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Maternal LAIV</title>
            <description>Healthy women who planned to breast feed through 28 days post vaccination received 0.2 mL of licensed live attenuated influenza vaccine (LAIV), Flumist®, intranasally, and 0.5 ml of sterile saline placebo by intramuscular injection.</description>
          </group>
          <group group_id="O2">
            <title>Maternal TIV</title>
            <description>Healthy women who planned to breast feed for 28 days post vaccination received 0.5 mL licensed seasonal trivalent influenza vaccine (TIV) by intramuscular injection, Fluzone®, by intramuscular injection, and 0.2 mL sucrose phosphate placebo intranasally.</description>
          </group>
          <group group_id="O3">
            <title>Infant LAIV</title>
            <description>Infants of women enrolled to receive LAIV were enrolled separately in the protocol to be followed for safety outcomes.</description>
          </group>
          <group group_id="O4">
            <title>Infant TIV</title>
            <description>Infants of women enrolled to receive TIV were enrolled separately in the protocol to be followed for safety outcomes.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Reporting New Onset Chronic Medical Conditions</title>
          <description>New onset chronic medical condition was defined as any new ICD-10 diagnosis for a participant that was expected to continue for at least 6 months and require continued health care intervention. ICD-10 = International Statistical Classification of Diseases and Related Health Problems, 10th revision. Maternal participants were asked at each visit through 180 days after enrollment if they or their infants had any new diagnosis.</description>
          <population>All enrolled participants are included in the analysis population for this outcome measure.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="124"/>
                <count group_id="O2" value="124"/>
                <count group_id="O3" value="124"/>
                <count group_id="O4" value="125"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Infant Participants Reporting Solicited Systemic Adverse Events Within 11 Days of Maternal Vaccination</title>
        <description>Maternal participants maintained a memory aid to record daily the occurrence in their infants of systemic adverse events of fever (defined as rectal temperature 37.8 degrees Celsius or greater), drowsiness, irritability/fussiness, loss of appetite, nasal congestion, difficulty breathing, runny nose, and cough for 11 days (Day 0-10) after maternal vaccination based on protocol-defined grading (none, mild, moderate or severe) for each symptom. Rectal temperature was measured once daily. Participants are counted if they were reported as experiencing the symptom at any severity on any of the 11 days.</description>
        <time_frame>Day 0 to Day 10 post vaccination</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Infant LAIV</title>
            <description>Infants of women enrolled to receive LAIV were enrolled separately in the protocol to be followed for safety outcomes.</description>
          </group>
          <group group_id="O2">
            <title>Infant TIV</title>
            <description>Infants of women enrolled to receive TIV were enrolled separately in the protocol to be followed for safety outcomes.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Infant Participants Reporting Solicited Systemic Adverse Events Within 11 Days of Maternal Vaccination</title>
          <description>Maternal participants maintained a memory aid to record daily the occurrence in their infants of systemic adverse events of fever (defined as rectal temperature 37.8 degrees Celsius or greater), drowsiness, irritability/fussiness, loss of appetite, nasal congestion, difficulty breathing, runny nose, and cough for 11 days (Day 0-10) after maternal vaccination based on protocol-defined grading (none, mild, moderate or severe) for each symptom. Rectal temperature was measured once daily. Participants are counted if they were reported as experiencing the symptom at any severity on any of the 11 days.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="124"/>
                <count group_id="O2" value="125"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Drowsiness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42"/>
                    <measurement group_id="O2" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability/fussiness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74"/>
                    <measurement group_id="O2" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Loss of appetite</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nasal congestion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54"/>
                    <measurement group_id="O2" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Difficulty breathing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Runny nose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cough</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participating Reporting Non-serious Unsolicited Adverse Events Related to Vaccination Within 28 Days of Maternal Vaccination</title>
        <description>Adverse events (AE) for this protocol used the International Conference on Harmonization (ICH) guideline E6 definition of AE, any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product regardless of its causal relationship to the study treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of investigational product. Related was defined as a reasonable possibility that the study product caused the AE. Reasonable possibility means that there is evidence to suggest a causal relationship between the study product and the adverse event. Non-serious AEs were those that did not meet the definition of serious (see Outcome Measure 1). Maternal participants were queried at each visit through 28 days after vaccination for the occurrence of any AE for her or the infant separately from the pre-defined solicited symptoms.</description>
        <time_frame>Day 0 to Day 28 post vaccination</time_frame>
        <population>All enrolled participants are included in the analysis population for this outcome measure</population>
        <group_list>
          <group group_id="O1">
            <title>Maternal LAIV</title>
            <description>Healthy women who planned to breast feed through 28 days post vaccination received 0.2 mL of licensed live attenuated influenza vaccine (LAIV), Flumist®, intranasally, and 0.5 ml of sterile saline placebo by intramuscular injection.</description>
          </group>
          <group group_id="O2">
            <title>Maternal TIV</title>
            <description>Healthy women who planned to breast feed for 28 days post vaccination received 0.5 mL licensed seasonal trivalent influenza vaccine (TIV) by intramuscular injection, Fluzone®, by intramuscular injection, and 0.2 mL sucrose phosphate placebo intranasally.</description>
          </group>
          <group group_id="O3">
            <title>Infant LAIV</title>
            <description>Infants of women enrolled to receive LAIV were enrolled separately in the protocol to be followed for safety outcomes.</description>
          </group>
          <group group_id="O4">
            <title>Infant TIV</title>
            <description>Infants of women enrolled to receive TIV were enrolled separately in the protocol to be followed for safety outcomes.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participating Reporting Non-serious Unsolicited Adverse Events Related to Vaccination Within 28 Days of Maternal Vaccination</title>
          <description>Adverse events (AE) for this protocol used the International Conference on Harmonization (ICH) guideline E6 definition of AE, any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product regardless of its causal relationship to the study treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of investigational product. Related was defined as a reasonable possibility that the study product caused the AE. Reasonable possibility means that there is evidence to suggest a causal relationship between the study product and the adverse event. Non-serious AEs were those that did not meet the definition of serious (see Outcome Measure 1). Maternal participants were queried at each visit through 28 days after vaccination for the occurrence of any AE for her or the infant separately from the pre-defined solicited symptoms.</description>
          <population>All enrolled participants are included in the analysis population for this outcome measure</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="124"/>
                <count group_id="O2" value="124"/>
                <count group_id="O3" value="124"/>
                <count group_id="O4" value="125"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Breast Milk ELISA IgA and IgG Geometric Mean Titers (GMT) to Each of the Vaccine Influenza Strains</title>
        <description>Breast milk was collected at Day 0 prior to vaccination and again at 28 days following vaccination for testing in IgA and IgG ELISA Assays. The ELISA assay was conducted with the antigens in the 2011-2012 seasonal influenza vaccine, A/Perth/16/2009 (H3N2) and B/Brisbane/60/2008, those in the 2012-2013 seasonal influenza vaccine, A/Victoria/361/2011 and B/Wisconsin/1/2010, and the antigen in both seasons's vaccine, A/California/7/2009 (H1N1). The lower limit of detection is 5.82 units/mL for IgA and 2.56 units/mL for IgG. Titers below the limit of detection were reported as one-half the limit of detection.</description>
        <time_frame>Day 0 and 28 post vaccination</time_frame>
        <population>All enrolled maternal participants are included in this analysis population.</population>
        <group_list>
          <group group_id="O1">
            <title>Maternal LAIV 2011-2012</title>
            <description>Healthy women who planned to breast feed through 28 days post vaccination received 0.2 mL of licensed live attenuated influenza vaccine (LAIV), Flumist®, intranasally in the 2011-2012 season</description>
          </group>
          <group group_id="O2">
            <title>Maternal LAIV 2012-2013</title>
            <description>Healthy women who planned to breast feed through 28 days post vaccination received 0.2 mL of licensed live attenuated influenza vaccine (LAIV), Flumist®, intranasally in the 2012-2013 season</description>
          </group>
          <group group_id="O3">
            <title>Maternal TIV 2011-2012</title>
            <description>Healthy women who planned to breast feed for 28 days post vaccination received 0.5 mL licensed seasonal trivalent influenza vaccine (TIV) by intramuscular injection, Fluzone®, by intramuscular injection in the 2011-2012 season</description>
          </group>
          <group group_id="O4">
            <title>Maternal TIV 2012-2013</title>
            <description>Healthy women who planned to breast feed for 28 days post vaccination received 0.5 mL licensed seasonal trivalent influenza vaccine (TIV) by intramuscular injection, Fluzone®, by intramuscular injection in the 2012-2013 season</description>
          </group>
        </group_list>
        <measure>
          <title>Breast Milk ELISA IgA and IgG Geometric Mean Titers (GMT) to Each of the Vaccine Influenza Strains</title>
          <description>Breast milk was collected at Day 0 prior to vaccination and again at 28 days following vaccination for testing in IgA and IgG ELISA Assays. The ELISA assay was conducted with the antigens in the 2011-2012 seasonal influenza vaccine, A/Perth/16/2009 (H3N2) and B/Brisbane/60/2008, those in the 2012-2013 seasonal influenza vaccine, A/Victoria/361/2011 and B/Wisconsin/1/2010, and the antigen in both seasons's vaccine, A/California/7/2009 (H1N1). The lower limit of detection is 5.82 units/mL for IgA and 2.56 units/mL for IgG. Titers below the limit of detection were reported as one-half the limit of detection.</description>
          <population>All enrolled maternal participants are included in this analysis population.</population>
          <units>units/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="48"/>
                <count group_id="O3" value="74"/>
                <count group_id="O4" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 0 IgA to A/California/7/2009 (H1N1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.8" lower_limit="6.6" upper_limit="11.7"/>
                    <measurement group_id="O2" value="8.6" lower_limit="6.1" upper_limit="12.2"/>
                    <measurement group_id="O3" value="8.7" lower_limit="6.3" upper_limit="12.0"/>
                    <measurement group_id="O4" value="7.5" lower_limit="5.1" upper_limit="11.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28 IgA to A/California/7/2009 (H1N1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.0" lower_limit="6.6" upper_limit="12.4"/>
                    <measurement group_id="O2" value="10.5" lower_limit="7.5" upper_limit="14.7"/>
                    <measurement group_id="O3" value="23.2" lower_limit="15.2" upper_limit="35.4"/>
                    <measurement group_id="O4" value="10.8" lower_limit="7.4" upper_limit="15.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 0 IgA to A/Perth/16/2009 (H3N2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.9" lower_limit="17.1" upper_limit="30.6"/>
                    <measurement group_id="O2" value="32.8" lower_limit="24.4" upper_limit="44.2"/>
                    <measurement group_id="O3" value="20.9" lower_limit="15.5" upper_limit="28.1"/>
                    <measurement group_id="O4" value="23.8" lower_limit="15.7" upper_limit="36.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28 IgA to A/Perth/16/2009 (H3N2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.3" lower_limit="21.3" upper_limit="40.2"/>
                    <measurement group_id="O2" value="50.8" lower_limit="37.1" upper_limit="69.4"/>
                    <measurement group_id="O3" value="44.2" lower_limit="31.6" upper_limit="61.8"/>
                    <measurement group_id="O4" value="38.9" lower_limit="25.0" upper_limit="60.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 0 IgA to A/Victoria/361/2011 (H3N2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.5" lower_limit="16.7" upper_limit="30.4"/>
                    <measurement group_id="O2" value="33.9" lower_limit="23.6" upper_limit="48.7"/>
                    <measurement group_id="O3" value="22.7" lower_limit="16.8" upper_limit="30.7"/>
                    <measurement group_id="O4" value="24.7" lower_limit="16.6" upper_limit="36.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28 IgA to A/Victoria/361/2011 (H3N2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.5" lower_limit="20.7" upper_limit="39.1"/>
                    <measurement group_id="O2" value="51.8" lower_limit="37.9" upper_limit="70.9"/>
                    <measurement group_id="O3" value="46.0" lower_limit="32.7" upper_limit="64.5"/>
                    <measurement group_id="O4" value="44.2" lower_limit="28.3" upper_limit="69.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 0 IgA to B/Brisbane/60/2008</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.1" lower_limit="13.4" upper_limit="21.8"/>
                    <measurement group_id="O2" value="15.9" lower_limit="11.1" upper_limit="22.7"/>
                    <measurement group_id="O3" value="12.9" lower_limit="9.8" upper_limit="16.8"/>
                    <measurement group_id="O4" value="15.1" lower_limit="10.9" upper_limit="20.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28 IgA to B/Brisbane/60/2008</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.9" lower_limit="17.2" upper_limit="30.3"/>
                    <measurement group_id="O2" value="22.0" lower_limit="15.0" upper_limit="32.3"/>
                    <measurement group_id="O3" value="23.9" lower_limit="17.4" upper_limit="32.8"/>
                    <measurement group_id="O4" value="23.4" lower_limit="16.5" upper_limit="33.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 0 IgA to B/Wisconsin/1/2010</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.2" lower_limit="6.4" upper_limit="10.6"/>
                    <measurement group_id="O2" value="10.0" lower_limit="7.1" upper_limit="14.1"/>
                    <measurement group_id="O3" value="8.3" lower_limit="6.3" upper_limit="10.8"/>
                    <measurement group_id="O4" value="7.5" lower_limit="5.6" upper_limit="10.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28 IgA to B/Wisconsin/1/2010</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.6" lower_limit="7.9" upper_limit="14.1"/>
                    <measurement group_id="O2" value="15.3" lower_limit="9.9" upper_limit="23.5"/>
                    <measurement group_id="O3" value="10.7" lower_limit="7.9" upper_limit="14.6"/>
                    <measurement group_id="O4" value="21.2" lower_limit="13.6" upper_limit="33.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 0 IgG to A/California/7/2009 (H1N1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" lower_limit="1.4" upper_limit="1.8"/>
                    <measurement group_id="O2" value="1.6" lower_limit="1.3" upper_limit="1.9"/>
                    <measurement group_id="O3" value="1.7" lower_limit="1.5" upper_limit="2.0"/>
                    <measurement group_id="O4" value="1.7" lower_limit="1.4" upper_limit="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28 IgG to A/California/7/2009 (H1N1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" lower_limit="1.4" upper_limit="1.8"/>
                    <measurement group_id="O2" value="1.6" lower_limit="1.4" upper_limit="1.9"/>
                    <measurement group_id="O3" value="5.0" lower_limit="3.7" upper_limit="6.7"/>
                    <measurement group_id="O4" value="2.9" lower_limit="2.2" upper_limit="3.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 0 IgG to A/Perth/16/2009 (H3N2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4" lower_limit="2.0" upper_limit="2.9"/>
                    <measurement group_id="O2" value="2.6" lower_limit="2.1" upper_limit="3.4"/>
                    <measurement group_id="O3" value="2.1" lower_limit="1.7" upper_limit="2.5"/>
                    <measurement group_id="O4" value="2.7" lower_limit="2.0" upper_limit="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28 IgG to A/Perth/16/2009 (H3N2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3" lower_limit="1.9" upper_limit="2.9"/>
                    <measurement group_id="O2" value="2.9" lower_limit="2.3" upper_limit="3.8"/>
                    <measurement group_id="O3" value="5.5" lower_limit="4.3" upper_limit="7.2"/>
                    <measurement group_id="O4" value="6.7" lower_limit="5.0" upper_limit="8.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 0 IgG to A/Victoria/361/2011 (H3N2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6" lower_limit="2.1" upper_limit="3.3"/>
                    <measurement group_id="O2" value="2.9" lower_limit="2.3" upper_limit="3.8"/>
                    <measurement group_id="O3" value="2.3" lower_limit="1.9" upper_limit="2.8"/>
                    <measurement group_id="O4" value="2.7" lower_limit="2.0" upper_limit="3.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28 IgG to A/Victoria/361/2011 (H3N2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.9" lower_limit="2.3" upper_limit="3.6"/>
                    <measurement group_id="O2" value="3.5" lower_limit="2.6" upper_limit="4.5"/>
                    <measurement group_id="O3" value="6.0" lower_limit="4.5" upper_limit="7.8"/>
                    <measurement group_id="O4" value="7.7" lower_limit="5.7" upper_limit="10.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 0 IgG to B/Brisbane/60/2008</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6" lower_limit="2.0" upper_limit="3.2"/>
                    <measurement group_id="O2" value="2.6" lower_limit="2.0" upper_limit="3.5"/>
                    <measurement group_id="O3" value="2.1" lower_limit="1.8" upper_limit="2.4"/>
                    <measurement group_id="O4" value="2.4" lower_limit="1.9" upper_limit="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28 IgG to B/Brisbane/60/2008</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7" lower_limit="2.2" upper_limit="3.4"/>
                    <measurement group_id="O2" value="2.9" lower_limit="2.2" upper_limit="3.8"/>
                    <measurement group_id="O3" value="4.9" lower_limit="3.7" upper_limit="6.3"/>
                    <measurement group_id="O4" value="4.2" lower_limit="3.2" upper_limit="5.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 0 IgG to B/Wisconsin/1/2010</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" lower_limit="1.4" upper_limit="1.9"/>
                    <measurement group_id="O2" value="1.6" lower_limit="1.3" upper_limit="1.8"/>
                    <measurement group_id="O3" value="1.5" lower_limit="1.3" upper_limit="1.6"/>
                    <measurement group_id="O4" value="1.6" lower_limit="1.3" upper_limit="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28 IgG to B/Wisconsin/1/2010</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" lower_limit="1.4" upper_limit="1.9"/>
                    <measurement group_id="O2" value="1.6" lower_limit="1.4" upper_limit="1.9"/>
                    <measurement group_id="O3" value="1.9" lower_limit="1.6" upper_limit="2.2"/>
                    <measurement group_id="O4" value="5.0" lower_limit="3.4" upper_limit="7.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Infant Participants With Medically Attended Respiratory or Gastrointestinal AEs 28-42 Days After Maternal Vaccination</title>
        <description>Maternal participants were contacted by telephone at Day 42 to report all medically attended respiratory or gastrointestinal adverse events occurring in the infant participants between 28 and 42 days after maternal vaccination.</description>
        <time_frame>Within 28-42 days after maternal vaccination</time_frame>
        <population>All infant participants for whom the maternal participants were contacted are included in the analysis population description. One maternal participant was not contacted.</population>
        <group_list>
          <group group_id="O1">
            <title>Infant LAIV</title>
            <description>Infants of women enrolled to receive LAIV were enrolled separately in the protocol to be followed for safety outcomes.</description>
          </group>
          <group group_id="O2">
            <title>Infant TIV</title>
            <description>Infants of women enrolled to receive TIV were enrolled separately in the protocol to be followed for safety outcomes.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Infant Participants With Medically Attended Respiratory or Gastrointestinal AEs 28-42 Days After Maternal Vaccination</title>
          <description>Maternal participants were contacted by telephone at Day 42 to report all medically attended respiratory or gastrointestinal adverse events occurring in the infant participants between 28 and 42 days after maternal vaccination.</description>
          <population>All infant participants for whom the maternal participants were contacted are included in the analysis population description. One maternal participant was not contacted.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="124"/>
                <count group_id="O2" value="125"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Respiratory AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gastrointestinal AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Titers (GMT) in Maternal Sera of Hemagglutination Inhibition (HAI) Antibodies to Each of the Influenza Strains in the Vaccine Received</title>
        <description>Blood was collected for HAI assay at Day 0 prior to vaccination and again at 28 days following vaccination. The HAI assay was conducted with the antigens in the 2011-2012 seasonal influenza vaccine, A/Perth/16/2009 (H3N2) and B/Brisbane/60/2008, those in the 2012-2013 seasonal influenza vaccine, A/Victoria/361/2011 and B/Wisconsin/1/2010, and the antigen in both seasons's vaccine, A/California/7/2009 (H1N1). The lower limit of detection for the assay was a titer of 10, sera samples below detection were given a value of 5 for analysis.</description>
        <time_frame>Day 0 and 28 post vaccination</time_frame>
        <population>All enrolled maternal participants with results reported are included in this analysis population.</population>
        <group_list>
          <group group_id="O1">
            <title>Maternal LAIV 2011-2012</title>
            <description>Healthy women who planned to breast feed through 28 days post vaccination received 0.2 mL of licensed live attenuated influenza vaccine (LAIV), Flumist®, intranasally in the 2011-2012 season</description>
          </group>
          <group group_id="O2">
            <title>Maternal LAIV 2012-2013</title>
            <description>Healthy women who planned to breast feed through 28 days post vaccination received 0.2 mL of licensed live attenuated influenza vaccine (LAIV), Flumist®, intranasally in the 2012-2013 season</description>
          </group>
          <group group_id="O3">
            <title>Maternal TIV 2011-2012</title>
            <description>Healthy women who planned to breast feed for 28 days post vaccination received 0.5 mL licensed seasonal trivalent influenza vaccine (TIV) by intramuscular injection, Fluzone®, by intramuscular injection in the 2011-2012 season</description>
          </group>
          <group group_id="O4">
            <title>Maternal TIV 2012-2013</title>
            <description>Healthy women who planned to breast feed for 28 days post vaccination received 0.5 mL licensed seasonal trivalent influenza vaccine (TIV) by intramuscular injection, Fluzone®, by intramuscular injection in the 2012-2013 season</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titers (GMT) in Maternal Sera of Hemagglutination Inhibition (HAI) Antibodies to Each of the Influenza Strains in the Vaccine Received</title>
          <description>Blood was collected for HAI assay at Day 0 prior to vaccination and again at 28 days following vaccination. The HAI assay was conducted with the antigens in the 2011-2012 seasonal influenza vaccine, A/Perth/16/2009 (H3N2) and B/Brisbane/60/2008, those in the 2012-2013 seasonal influenza vaccine, A/Victoria/361/2011 and B/Wisconsin/1/2010, and the antigen in both seasons's vaccine, A/California/7/2009 (H1N1). The lower limit of detection for the assay was a titer of 10, sera samples below detection were given a value of 5 for analysis.</description>
          <population>All enrolled maternal participants with results reported are included in this analysis population.</population>
          <units>titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
                <count group_id="O2" value="48"/>
                <count group_id="O3" value="74"/>
                <count group_id="O4" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 0 - A/Perth/16/2009 (H3N2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.5" lower_limit="32.6" upper_limit="63.5"/>
                    <measurement group_id="O2" value="53.0" lower_limit="36.1" upper_limit="77.8"/>
                    <measurement group_id="O3" value="32.9" lower_limit="23.5" upper_limit="46.0"/>
                    <measurement group_id="O4" value="52.1" lower_limit="37.7" upper_limit="71.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28 - A/Perth/16/2009 (H3N2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.6" lower_limit="37.2" upper_limit="71.5"/>
                    <measurement group_id="O2" value="59.9" lower_limit="41.6" upper_limit="86.2"/>
                    <measurement group_id="O3" value="119.7" lower_limit="88.2" upper_limit="162.4"/>
                    <measurement group_id="O4" value="133.6" lower_limit="103.7" upper_limit="172.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 0 - B/Brisbane/60/2008</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.2" lower_limit="16.2" upper_limit="25.1"/>
                    <measurement group_id="O2" value="18.2" lower_limit="14.2" upper_limit="23.4"/>
                    <measurement group_id="O3" value="15.7" lower_limit="12.8" upper_limit="19.2"/>
                    <measurement group_id="O4" value="17.5" lower_limit="14.1" upper_limit="21.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28 - B/Brisbane/60/2008</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.6" lower_limit="17.4" upper_limit="26.9"/>
                    <measurement group_id="O2" value="18.5" lower_limit="14.3" upper_limit="23.8"/>
                    <measurement group_id="O3" value="42.3" lower_limit="33.1" upper_limit="54.1"/>
                    <measurement group_id="O4" value="31.0" lower_limit="25.2" upper_limit="38.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 0 - A/Victoria/361/2011</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.0" lower_limit="33.2" upper_limit="66.6"/>
                    <measurement group_id="O2" value="60.4" lower_limit="42.5" upper_limit="85.7"/>
                    <measurement group_id="O3" value="38.0" lower_limit="26.6" upper_limit="54.2"/>
                    <measurement group_id="O4" value="62.8" lower_limit="43.7" upper_limit="90.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28 - A/Victoria/361/2011</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.3" lower_limit="39.7" upper_limit="79.8"/>
                    <measurement group_id="O2" value="81.2" lower_limit="60.1" upper_limit="109.6"/>
                    <measurement group_id="O3" value="207.0" lower_limit="161.1" upper_limit="265.9"/>
                    <measurement group_id="O4" value="247.6" lower_limit="194.2" upper_limit="315.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 0 - B/Wisconsin/1/2010</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.3" lower_limit="8.4" upper_limit="12.7"/>
                    <measurement group_id="O2" value="8.7" lower_limit="7.0" upper_limit="10.7"/>
                    <measurement group_id="O3" value="9.1" lower_limit="7.6" upper_limit="11.0"/>
                    <measurement group_id="O4" value="10.6" lower_limit="8.6" upper_limit="13.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28 - B/Wisconsin/1/2010</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.9" lower_limit="8.9" upper_limit="13.4"/>
                    <measurement group_id="O2" value="9.0" lower_limit="7.4" upper_limit="10.9"/>
                    <measurement group_id="O3" value="15.8" lower_limit="12.6" upper_limit="19.9"/>
                    <measurement group_id="O4" value="41.1" lower_limit="30.2" upper_limit="56.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 0 -A/California/7/2009 (H1N1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.7" lower_limit="31.9" upper_limit="62.6"/>
                    <measurement group_id="O2" value="44.6" lower_limit="31.6" upper_limit="63.0"/>
                    <measurement group_id="O3" value="42.9" lower_limit="30.1" upper_limit="61.1"/>
                    <measurement group_id="O4" value="64.1" lower_limit="43.1" upper_limit="95.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28 - A/California/7/2009 (H1N1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.8" lower_limit="33.6" upper_limit="65.1"/>
                    <measurement group_id="O2" value="44.9" lower_limit="31.8" upper_limit="63.4"/>
                    <measurement group_id="O3" value="382.3" lower_limit="284.3" upper_limit="514.2"/>
                    <measurement group_id="O4" value="197.0" lower_limit="146.1" upper_limit="265.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Maternal Participants With Season-specific LAIV Influenza A and B Strains Detected in Respiratory Secretions Prior to Vaccination.</title>
        <description>Nasal swab samples were collected from all maternal participants prior to vaccination for PCR and cell culture to assess for the presence of the viruses in the LAIV vaccine in respiratory secretions. The data coordinating center selected 25% of participants in the TIV group for testing to serve as an internal control for the assay.</description>
        <time_frame>Day 0 prior to vaccination</time_frame>
        <population>All participants with samples selected for testing by the data coordinating center, 100% of LAIV recipients and 25% of TIV recipients, are included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Maternal LAIV 2011-2012</title>
            <description>Healthy women who planned to breast feed through 28 days post vaccination received 0.2 mL of licensed live attenuated influenza vaccine (LAIV), Flumist®, intranasally in the 2011-2012 season</description>
          </group>
          <group group_id="O2">
            <title>Maternal LAIV 2012-2013</title>
            <description>Healthy women who planned to breast feed through 28 days post vaccination received 0.2 mL of licensed live attenuated influenza vaccine (LAIV), Flumist®, intranasally in the 2012-2013 season</description>
          </group>
          <group group_id="O3">
            <title>Maternal TIV 2011-2012</title>
            <description>Healthy women who planned to breast feed for 28 days post vaccination received 0.5 mL licensed seasonal trivalent influenza vaccine (TIV) by intramuscular injection, Fluzone®, by intramuscular injection in the 2011-2012 season</description>
          </group>
          <group group_id="O4">
            <title>Maternal TIV 2012-2013</title>
            <description>Healthy women who planned to breast feed for 28 days post vaccination received 0.5 mL licensed seasonal trivalent influenza vaccine (TIV) by intramuscular injection, Fluzone®, by intramuscular injection in the 2012-2013 season</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Maternal Participants With Season-specific LAIV Influenza A and B Strains Detected in Respiratory Secretions Prior to Vaccination.</title>
          <description>Nasal swab samples were collected from all maternal participants prior to vaccination for PCR and cell culture to assess for the presence of the viruses in the LAIV vaccine in respiratory secretions. The data coordinating center selected 25% of participants in the TIV group for testing to serve as an internal control for the assay.</description>
          <population>All participants with samples selected for testing by the data coordinating center, 100% of LAIV recipients and 25% of TIV recipients, are included in the analysis.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="48"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Influenza A - PCR negative, cell culture negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72"/>
                    <measurement group_id="O2" value="47"/>
                    <measurement group_id="O3" value="16"/>
                    <measurement group_id="O4" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Influenza A - PCR negative, cell culture positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Influenza A - PCR positive, cell culture negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Influenza A - PCR positive, cell culture positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Influenza B - PCR negative, cell culture negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72"/>
                    <measurement group_id="O2" value="48"/>
                    <measurement group_id="O3" value="16"/>
                    <measurement group_id="O4" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Influenza B - PCR negative, cell culture positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Influenza B - PCR positive, cell culture negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Influenza B - PCR positive, cell culture positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Maternal Participants With Season-specific LAIV Influenza A and B Strains Detected in Respiratory Secretions at Day 2 Post Vaccination.</title>
        <description>Nasal swab samples were collected from all maternal participants at Day 2 post vaccination for PCR and cell culture to assess for the presence of the viruses in the LAIV vaccine in respiratory secretions. The data coordinating center selected 25% of participants in the TIV group for testing to serve as an internal control for the assay.</description>
        <time_frame>Day 2 post vaccination</time_frame>
        <population>All participants with samples selected for testing by the data coordinating center, 100% of LAIV recipients and 25% of TIV recipients, are included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Maternal LAIV 2011-2012</title>
            <description>Healthy women who planned to breast feed through 28 days post vaccination received 0.2 mL of licensed live attenuated influenza vaccine (LAIV), Flumist®, intranasally in the 2011-2012 season</description>
          </group>
          <group group_id="O2">
            <title>Maternal LAIV 2012-2013</title>
            <description>Healthy women who planned to breast feed through 28 days post vaccination received 0.2 mL of licensed live attenuated influenza vaccine (LAIV), Flumist®, intranasally in the 2012-2013 season</description>
          </group>
          <group group_id="O3">
            <title>Maternal TIV 2011-2012</title>
            <description>Healthy women who planned to breast feed for 28 days post vaccination received 0.5 mL licensed seasonal trivalent influenza vaccine (TIV) by intramuscular injection, Fluzone®, by intramuscular injection in the 2011-2012 season</description>
          </group>
          <group group_id="O4">
            <title>Maternal TIV 2012-2013</title>
            <description>Healthy women who planned to breast feed for 28 days post vaccination received 0.5 mL licensed seasonal trivalent influenza vaccine (TIV) by intramuscular injection, Fluzone®, by intramuscular injection in the 2012-2013 season</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Maternal Participants With Season-specific LAIV Influenza A and B Strains Detected in Respiratory Secretions at Day 2 Post Vaccination.</title>
          <description>Nasal swab samples were collected from all maternal participants at Day 2 post vaccination for PCR and cell culture to assess for the presence of the viruses in the LAIV vaccine in respiratory secretions. The data coordinating center selected 25% of participants in the TIV group for testing to serve as an internal control for the assay.</description>
          <population>All participants with samples selected for testing by the data coordinating center, 100% of LAIV recipients and 25% of TIV recipients, are included in the analysis.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="47"/>
                <count group_id="O3" value="19"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Influenza A - PCR negative, cell culture negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51"/>
                    <measurement group_id="O2" value="41"/>
                    <measurement group_id="O3" value="19"/>
                    <measurement group_id="O4" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Influenza A - PCR negative, cell culture positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Influenza A - PCR positive, cell culture negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Influenza A - PCR positive, cell culture positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Influenza B - PCR negative, cell culture negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                    <measurement group_id="O2" value="30"/>
                    <measurement group_id="O3" value="19"/>
                    <measurement group_id="O4" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Influenza B - PCR negative, cell culture positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Influenza B - PCR positive, cell culture negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Influenza B - PCR positive, cell culture positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Maternal Participants Reporting Fever After Vaccination</title>
        <description>Participants were provided with a thermometer and a memory aid on which to record daily oral temperatures for 8 days after vaccination (Day 0-7). The protocol defined fever as oral temperature of 37.8 degrees Celsius or higher. Participants are counted as experiencing fever if they reported oral temperatures of 37.8 degrees Celsius or higher on any of the 8 days.</description>
        <time_frame>Day 0-7 post vaccination</time_frame>
        <population>All enrolled maternal participants are included in this analysis population.</population>
        <group_list>
          <group group_id="O1">
            <title>Maternal LAIV</title>
            <description>Healthy women who planned to breast feed through 28 days post vaccination received 0.2 mL of licensed live attenuated influenza vaccine (LAIV), Flumist®, intranasally, and 0.5 ml of sterile saline placebo by intramuscular injection.</description>
          </group>
          <group group_id="O2">
            <title>Maternal TIV</title>
            <description>Healthy women who planned to breast feed for 28 days post vaccination received 0.5 mL licensed seasonal trivalent influenza vaccine (TIV) by intramuscular injection, Fluzone®, by intramuscular injection, and 0.2 mL sucrose phosphate placebo intranasally.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Maternal Participants Reporting Fever After Vaccination</title>
          <description>Participants were provided with a thermometer and a memory aid on which to record daily oral temperatures for 8 days after vaccination (Day 0-7). The protocol defined fever as oral temperature of 37.8 degrees Celsius or higher. Participants are counted as experiencing fever if they reported oral temperatures of 37.8 degrees Celsius or higher on any of the 8 days.</description>
          <population>All enrolled maternal participants are included in this analysis population.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="124"/>
                <count group_id="O2" value="124"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Maternal Participants Reporting Solicited Subjective Systemic Symptoms After Vaccination</title>
        <description>Participants maintained a memory aid to record daily the occurrence of systemic symptoms of feverishness, malaise, myalgia, headache, nausea, weakness, and chills for 8 days after vaccination (Day 0-7) based on their interference with daily activities. Participants are counted if they reported experiencing the symptom at any severity on any of the 8 days.</description>
        <time_frame>Day 0-7 post vaccination</time_frame>
        <population>All enrolled maternal participants are included in this analysis population.</population>
        <group_list>
          <group group_id="O1">
            <title>Maternal LAIV</title>
            <description>Healthy women who planned to breast feed through 28 days post vaccination received 0.2 mL of licensed live attenuated influenza vaccine (LAIV), Flumist®, intranasally, and 0.5 ml of sterile saline placebo by intramuscular injection.</description>
          </group>
          <group group_id="O2">
            <title>Maternal TIV</title>
            <description>Healthy women who planned to breast feed for 28 days post vaccination received 0.5 mL licensed seasonal trivalent influenza vaccine (TIV) by intramuscular injection, Fluzone®, by intramuscular injection, and 0.2 mL sucrose phosphate placebo intranasally.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Maternal Participants Reporting Solicited Subjective Systemic Symptoms After Vaccination</title>
          <description>Participants maintained a memory aid to record daily the occurrence of systemic symptoms of feverishness, malaise, myalgia, headache, nausea, weakness, and chills for 8 days after vaccination (Day 0-7) based on their interference with daily activities. Participants are counted if they reported experiencing the symptom at any severity on any of the 8 days.</description>
          <population>All enrolled maternal participants are included in this analysis population.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="124"/>
                <count group_id="O2" value="124"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Feverishness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malaise</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45"/>
                    <measurement group_id="O2" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myalgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53"/>
                    <measurement group_id="O2" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Weakness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chills</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Maternal Participants Reporting Solicited Subjective Local Symptoms After Vaccination</title>
        <description>Participants maintained a memory aid to record daily the occurrence of local symptoms of nasal congestion, runny nose, cough, sore throat, nasal bleeding, pain at injection site, tenderness at injection site, and swelling at injection site for 8 days after vaccination (Day 0-7) based on their interference with daily activities. Participants are counted if they reported experiencing the symptom at any severity on any of the 8 days.</description>
        <time_frame>Day 0-7 post vaccination</time_frame>
        <population>All enrolled maternal participants are included in this analysis population.</population>
        <group_list>
          <group group_id="O1">
            <title>Maternal LAIV</title>
            <description>Healthy women who planned to breast feed through 28 days post vaccination received 0.2 mL of licensed live attenuated influenza vaccine (LAIV), Flumist®, intranasally, and 0.5 ml of sterile saline placebo by intramuscular injection.</description>
          </group>
          <group group_id="O2">
            <title>Maternal TIV</title>
            <description>Healthy women who planned to breast feed for 28 days post vaccination received 0.5 mL licensed seasonal trivalent influenza vaccine (TIV) by intramuscular injection, Fluzone®, by intramuscular injection, and 0.2 mL sucrose phosphate placebo intranasally.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Maternal Participants Reporting Solicited Subjective Local Symptoms After Vaccination</title>
          <description>Participants maintained a memory aid to record daily the occurrence of local symptoms of nasal congestion, runny nose, cough, sore throat, nasal bleeding, pain at injection site, tenderness at injection site, and swelling at injection site for 8 days after vaccination (Day 0-7) based on their interference with daily activities. Participants are counted if they reported experiencing the symptom at any severity on any of the 8 days.</description>
          <population>All enrolled maternal participants are included in this analysis population.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="124"/>
                <count group_id="O2" value="124"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Nasal congestion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56"/>
                    <measurement group_id="O2" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Runny nose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51"/>
                    <measurement group_id="O2" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cough</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sore throat</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                    <measurement group_id="O2" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nasal bleeding</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain at Injection Site</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tenderness at injection site</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling at injection site</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Maternal Participants Reporting Solicited Quantitative Local Symptoms After Vaccination</title>
        <description>Participants maintained a memory aid to record daily the occurrence of local reactions of redness and swelling for 8 days after vaccination (Day 0-7). If the reaction was present, the maximum diameter was measured in millimeters (mm). Participants are counted if they reported experiencing the reaction with any measurement greater than 0 mm on any of the 8 days.</description>
        <time_frame>Day 0-7 post vaccination</time_frame>
        <population>All enrolled maternal participants are included in this analysis population.</population>
        <group_list>
          <group group_id="O1">
            <title>Maternal LAIV</title>
            <description>Healthy women who planned to breast feed through 28 days post vaccination received 0.2 mL of licensed live attenuated influenza vaccine (LAIV), Flumist®, intranasally, and 0.5 ml of sterile saline placebo by intramuscular injection.</description>
          </group>
          <group group_id="O2">
            <title>Maternal TIV</title>
            <description>Healthy women who planned to breast feed for 28 days post vaccination received 0.5 mL licensed seasonal trivalent influenza vaccine (TIV) by intramuscular injection, Fluzone®, by intramuscular injection, and 0.2 mL sucrose phosphate placebo intranasally.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Maternal Participants Reporting Solicited Quantitative Local Symptoms After Vaccination</title>
          <description>Participants maintained a memory aid to record daily the occurrence of local reactions of redness and swelling for 8 days after vaccination (Day 0-7). If the reaction was present, the maximum diameter was measured in millimeters (mm). Participants are counted if they reported experiencing the reaction with any measurement greater than 0 mm on any of the 8 days.</description>
          <population>All enrolled maternal participants are included in this analysis population.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="124"/>
                <count group_id="O2" value="124"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Redness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Maternal Participants With Season-specific LAIV Influenza A and B Strains Detected in Respiratory Secretions at Day 8 Post Vaccination.</title>
        <description>Nasal swab samples were collected from all maternal participants at Day 8 post vaccination for PCR and cell culture to assess for the presence of the viruses in the LAIV vaccine in respiratory secretions. The data coordinating center selected 25% of participants in the TIV group for testing to serve as an internal control for the assay.</description>
        <time_frame>Day 8 post vaccination</time_frame>
        <population>All participants with samples selected for testing by the data coordinating center, 100% of LAIV recipients and 25% of TIV recipients, are included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Maternal LAIV 2011-2012</title>
            <description>Healthy women who planned to breast feed through 28 days post vaccination received 0.2 mL of licensed live attenuated influenza vaccine (LAIV), Flumist®, intranasally in the 2011-2012 season</description>
          </group>
          <group group_id="O2">
            <title>Maternal LAIV 2012-2013</title>
            <description>Healthy women who planned to breast feed through 28 days post vaccination received 0.2 mL of licensed live attenuated influenza vaccine (LAIV), Flumist®, intranasally in the 2012-2013 season</description>
          </group>
          <group group_id="O3">
            <title>Maternal TIV 2011-2012</title>
            <description>Healthy women who planned to breast feed for 28 days post vaccination received 0.5 mL licensed seasonal trivalent influenza vaccine (TIV) by intramuscular injection, Fluzone®, by intramuscular injection in the 2011-2012 season</description>
          </group>
          <group group_id="O4">
            <title>Maternal TIV 2012-2013</title>
            <description>Healthy women who planned to breast feed for 28 days post vaccination received 0.5 mL licensed seasonal trivalent influenza vaccine (TIV) by intramuscular injection, Fluzone®, by intramuscular injection in the 2012-2013 season</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Maternal Participants With Season-specific LAIV Influenza A and B Strains Detected in Respiratory Secretions at Day 8 Post Vaccination.</title>
          <description>Nasal swab samples were collected from all maternal participants at Day 8 post vaccination for PCR and cell culture to assess for the presence of the viruses in the LAIV vaccine in respiratory secretions. The data coordinating center selected 25% of participants in the TIV group for testing to serve as an internal control for the assay.</description>
          <population>All participants with samples selected for testing by the data coordinating center, 100% of LAIV recipients and 25% of TIV recipients, are included in the analysis.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="47"/>
                <count group_id="O3" value="19"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Influenza A - PCR negative, cell culture negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71"/>
                    <measurement group_id="O2" value="47"/>
                    <measurement group_id="O3" value="19"/>
                    <measurement group_id="O4" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Influenza A - PCR negative, cell culture positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Influenza A - PCR positive, cell culture negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Influenza A - PCR positive, cell culture positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Influenza B - PCR negative, cell culture negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65"/>
                    <measurement group_id="O2" value="43"/>
                    <measurement group_id="O3" value="19"/>
                    <measurement group_id="O4" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Influenza B - PCR negative, cell culture positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Influenza B - PCR positive, cell culture negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Influenza B - PCR positive, cell culture positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Infant Participants With Season-specific LAIV Influenza A and B Strains Detected in Respiratory Secretions Prior to Vaccination.</title>
        <description>Nasal swab samples were collected from all infant participants prior to vaccination for PCR and cell culture to assess for the presence of the viruses in the LAIV vaccine in respiratory secretions. The data coordinating center selected 25% of participants in the TIV group for testing to serve as an internal control for the assay.</description>
        <time_frame>Day 0 prior to vaccination</time_frame>
        <population>All participants with samples selected for testing by the data coordinating center, 100% of LAIV recipients and 25% of TIV recipients, are included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Infant LAIV 2011-2012</title>
            <description>Infants of women enrolled to receive LAIV in the 2011-2012 season were enrolled separately in the protocol to be followed for safety outcomes.</description>
          </group>
          <group group_id="O2">
            <title>Infant LAIV 2012-2013</title>
            <description>Infants of women enrolled to receive LAIV in the 2012-2013 season were enrolled separately in the protocol to be followed for safety outcomes.</description>
          </group>
          <group group_id="O3">
            <title>Infant TIV 2011-2012</title>
            <description>Infants of women enrolled to receive TIV in the 2011-2012 season were enrolled separately in the protocol to be followed for safety outcomes.</description>
          </group>
          <group group_id="O4">
            <title>Infant TIV 2012-2013</title>
            <description>Infants of women enrolled to receive TIV in the 2012-2013 season were enrolled separately in the protocol to be followed for safety outcomes.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Infant Participants With Season-specific LAIV Influenza A and B Strains Detected in Respiratory Secretions Prior to Vaccination.</title>
          <description>Nasal swab samples were collected from all infant participants prior to vaccination for PCR and cell culture to assess for the presence of the viruses in the LAIV vaccine in respiratory secretions. The data coordinating center selected 25% of participants in the TIV group for testing to serve as an internal control for the assay.</description>
          <population>All participants with samples selected for testing by the data coordinating center, 100% of LAIV recipients and 25% of TIV recipients, are included in the analysis.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
                <count group_id="O2" value="48"/>
                <count group_id="O3" value="19"/>
                <count group_id="O4" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Influenza A - PCR negative, cell culture negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71"/>
                    <measurement group_id="O2" value="48"/>
                    <measurement group_id="O3" value="19"/>
                    <measurement group_id="O4" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Influenza A - PCR negative, cell culture positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Influenza A - PCR positive, cell culture negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Influenza A - PCR positive, cell culture positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Influenza B - PCR negative, cell culture negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71"/>
                    <measurement group_id="O2" value="48"/>
                    <measurement group_id="O3" value="19"/>
                    <measurement group_id="O4" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Influenza B - PCR negative, cell culture positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Influenza B - PCR positive, cell culture negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Influenza B - PCR positive, cell culture positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Infant Participants With Season-specific LAIV Influenza A and B Strains Detected in Respiratory Secretions at Day 2 Post Vaccination.</title>
        <description>Nasal swab samples were collected from all infant participants at Day 2 post vaccination for PCR and cell culture to assess for the presence of the viruses in the LAIV vaccine in respiratory secretions. The data coordinating center selected 25% of participants in the TIV group for testing to serve as an internal control for the assay.</description>
        <time_frame>Day 2 post vaccination</time_frame>
        <population>All participants with samples selected for testing by the data coordinating center, 100% of LAIV recipients and 25% of TIV recipients, are included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Infant LAIV 2011-2012</title>
            <description>Infants of women enrolled to receive LAIV in the 2011-2012 season were enrolled separately in the protocol to be followed for safety outcomes.</description>
          </group>
          <group group_id="O2">
            <title>Infant LAIV 2012-2013</title>
            <description>Infants of women enrolled to receive LAIV in the 2012-2013 season were enrolled separately in the protocol to be followed for safety outcomes.</description>
          </group>
          <group group_id="O3">
            <title>Infant TIV 2011-2012</title>
            <description>Infants of women enrolled to receive TIV in the 2011-2012 season were enrolled separately in the protocol to be followed for safety outcomes.</description>
          </group>
          <group group_id="O4">
            <title>Infant TIV 2012-2013</title>
            <description>Infants of women enrolled to receive TIV in the 2012-2013 season were enrolled separately in the protocol to be followed for safety outcomes.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Infant Participants With Season-specific LAIV Influenza A and B Strains Detected in Respiratory Secretions at Day 2 Post Vaccination.</title>
          <description>Nasal swab samples were collected from all infant participants at Day 2 post vaccination for PCR and cell culture to assess for the presence of the viruses in the LAIV vaccine in respiratory secretions. The data coordinating center selected 25% of participants in the TIV group for testing to serve as an internal control for the assay.</description>
          <population>All participants with samples selected for testing by the data coordinating center, 100% of LAIV recipients and 25% of TIV recipients, are included in the analysis.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="44"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Influenza A - PCR negative, cell culture negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71"/>
                    <measurement group_id="O2" value="44"/>
                    <measurement group_id="O3" value="20"/>
                    <measurement group_id="O4" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Influenza A - PCR negative, cell culture positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Influenza A - PCR positive, cell culture negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Influenza A - PCR positive, cell culture positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Influenza B - PCR negative, cell culture negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72"/>
                    <measurement group_id="O2" value="44"/>
                    <measurement group_id="O3" value="20"/>
                    <measurement group_id="O4" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Influenza B - PCR negative, cell culture positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Influenza B - PCR positive, cell culture negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Influenza B - PCR positive, cell culture positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Infant Participants With Season-specific LAIV Influenza A and B Strains Detected in Respiratory Secretions at Day 8 Post Vaccination.</title>
        <description>Nasal swab samples were collected from all infant participants at Day 8 post vaccination for PCR and cell culture to assess for the presence of the viruses in the LAIV vaccine in respiratory secretions. The data coordinating center selected 25% of participants in the TIV group for testing to serve as an internal control for the assay.</description>
        <time_frame>Day 8 post vaccination</time_frame>
        <population>All participants with samples selected for testing by the data coordinating center, 100% of LAIV recipients and 25% of TIV recipients, are included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Infant LAIV 2011-2012</title>
            <description>Infants of women enrolled to receive LAIV in the 2011-2012 season were enrolled separately in the protocol to be followed for safety outcomes.</description>
          </group>
          <group group_id="O2">
            <title>Infant LAIV 2012-2013</title>
            <description>Infants of women enrolled to receive LAIV in the 2012-2013 season were enrolled separately in the protocol to be followed for safety outcomes.</description>
          </group>
          <group group_id="O3">
            <title>Infant TIV 2011-2012</title>
            <description>Infants of women enrolled to receive TIV in the 2011-2012 season were enrolled separately in the protocol to be followed for safety outcomes.</description>
          </group>
          <group group_id="O4">
            <title>Infant TIV 2012-2013</title>
            <description>Infants of women enrolled to receive TIV in the 2012-2013 season were enrolled separately in the protocol to be followed for safety outcomes.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Infant Participants With Season-specific LAIV Influenza A and B Strains Detected in Respiratory Secretions at Day 8 Post Vaccination.</title>
          <description>Nasal swab samples were collected from all infant participants at Day 8 post vaccination for PCR and cell culture to assess for the presence of the viruses in the LAIV vaccine in respiratory secretions. The data coordinating center selected 25% of participants in the TIV group for testing to serve as an internal control for the assay.</description>
          <population>All participants with samples selected for testing by the data coordinating center, 100% of LAIV recipients and 25% of TIV recipients, are included in the analysis.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="47"/>
                <count group_id="O3" value="19"/>
                <count group_id="O4" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Influenza A - PCR negative, cell culture negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72"/>
                    <measurement group_id="O2" value="47"/>
                    <measurement group_id="O3" value="19"/>
                    <measurement group_id="O4" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Influenza A - PCR negative, cell culture positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Influenza A - PCR positive, cell culture negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Influenza A - PCR positive, cell culture positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Influenza B - PCR negative, cell culture negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72"/>
                    <measurement group_id="O2" value="47"/>
                    <measurement group_id="O3" value="19"/>
                    <measurement group_id="O4" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Influenza B - PCR negative, cell culture positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Influenza B - PCR positive, cell culture negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Influenza B - PCR positive, cell culture positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Maternal Participants Positive for the Season-specific LAIV Influenza A Strain in Respiratory Secretions at Day 0 Who Were Positive for H1N1 and/or H3N2 Strains.</title>
        <description>Nasal swab samples were collected from all maternal participants prior to vaccination for PCR and cell culture to assess for the presence of the viruses in the LAIV vaccine in respiratory secretions. Those who were positive for the Influenza A strain were further tested to identify the H1N1 and H3N2 strain.</description>
        <time_frame>Day 0 prior to vaccination</time_frame>
        <population>The analysis population is limited to participants who were positive by PCR and/or cell culture for the vaccine strain of Influenza A.</population>
        <group_list>
          <group group_id="O1">
            <title>Maternal LAIV 2012-2013</title>
            <description>Healthy women who planned to breast feed through 28 days post vaccination received 0.2 mL of licensed live attenuated influenza vaccine (LAIV), Flumist®, intranasally in the 2012-2013 season</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Maternal Participants Positive for the Season-specific LAIV Influenza A Strain in Respiratory Secretions at Day 0 Who Were Positive for H1N1 and/or H3N2 Strains.</title>
          <description>Nasal swab samples were collected from all maternal participants prior to vaccination for PCR and cell culture to assess for the presence of the viruses in the LAIV vaccine in respiratory secretions. Those who were positive for the Influenza A strain were further tested to identify the H1N1 and H3N2 strain.</description>
          <population>The analysis population is limited to participants who were positive by PCR and/or cell culture for the vaccine strain of Influenza A.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H1N1 - PCR negative, cell culture negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H1N1 - PCR negative, cell culture positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H1N1 - PCR positive, cell culture negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H1N1 - PCR positive, cell culture positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2 - PCR negative, cell culture negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2 - PCR negative, cell culture positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2 - PCR positive, cell culture negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2 - PCR positive, cell culture positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Maternal and Infant Participants Positive for the Season-specific LAIV Influenza A Strain in Respiratory Secretions at Day 2 Who Were Positive for H1N1 and/or H3N2 Strains.</title>
        <description>Nasal swab samples were collected from all maternal and infant participants at Day 2 post vaccination for PCR and cell culture to assess for the presence of the viruses in the LAIV vaccine in respiratory secretions. Those who were positive for the Influenza A strain were further tested to identify the H1N1 and H3N2 strain.</description>
        <time_frame>Day 2 post vaccination</time_frame>
        <population>The analysis population is limited to participants who were positive by PCR and/or cell culture for the vaccine strain of Influenza A.</population>
        <group_list>
          <group group_id="O1">
            <title>Maternal LAIV 2011-2012</title>
            <description>Healthy women who planned to breast feed through 28 days post vaccination received 0.2 mL of licensed live attenuated influenza vaccine (LAIV), Flumist®, intranasally in the 2011-2012 season</description>
          </group>
          <group group_id="O2">
            <title>Maternal LAIV 2012-2013</title>
            <description>Healthy women who planned to breast feed through 28 days post vaccination received 0.2 mL of licensed live attenuated influenza vaccine (LAIV), Flumist®, intranasally in the 2012-2013 season</description>
          </group>
          <group group_id="O3">
            <title>Infant LAIV 2011-2012</title>
            <description>Infants of women enrolled to receive LAIV in the 2011-2012 season were enrolled separately in the protocol to be followed for safety outcomes.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Maternal and Infant Participants Positive for the Season-specific LAIV Influenza A Strain in Respiratory Secretions at Day 2 Who Were Positive for H1N1 and/or H3N2 Strains.</title>
          <description>Nasal swab samples were collected from all maternal and infant participants at Day 2 post vaccination for PCR and cell culture to assess for the presence of the viruses in the LAIV vaccine in respiratory secretions. Those who were positive for the Influenza A strain were further tested to identify the H1N1 and H3N2 strain.</description>
          <population>The analysis population is limited to participants who were positive by PCR and/or cell culture for the vaccine strain of Influenza A.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H1N1 - PCR negative, cell culture negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H1N1 - PCR negative, cell culture positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H1N1 - PCR positive, cell culture negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H1N1 - PCR positive, cell culture positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2 - PCR negative, cell culture negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2 - PCR negative, cell culture positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2 - PCR positive, cell culture negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2 - PCR positive, cell culture positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Maternal Participants Positive for the Season-specific LAIV Influenza A Strain in Respiratory Secretions at Day 8 Who Were Positive for H1N1 and/or H3N2 Strains.</title>
        <description>Nasal swab samples were collected from all maternal participants at Day 8 post vaccination for PCR and cell culture to assess for the presence of the viruses in the LAIV vaccine in respiratory secretions. Those who were positive for the Influenza A strain were further tested to identify the H1N1 and H3N2 strain.</description>
        <time_frame>Day 8 post vaccination</time_frame>
        <population>The analysis population is limited to participants who were positive by PCR and/or cell culture for the vaccine strain of Influenza A.</population>
        <group_list>
          <group group_id="O1">
            <title>Maternal LAIV 2011-2012</title>
            <description>Healthy women who planned to breast feed through 28 days post vaccination received 0.2 mL of licensed live attenuated influenza vaccine (LAIV), Flumist®, intranasally in the 2011-2012 season</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Maternal Participants Positive for the Season-specific LAIV Influenza A Strain in Respiratory Secretions at Day 8 Who Were Positive for H1N1 and/or H3N2 Strains.</title>
          <description>Nasal swab samples were collected from all maternal participants at Day 8 post vaccination for PCR and cell culture to assess for the presence of the viruses in the LAIV vaccine in respiratory secretions. Those who were positive for the Influenza A strain were further tested to identify the H1N1 and H3N2 strain.</description>
          <population>The analysis population is limited to participants who were positive by PCR and/or cell culture for the vaccine strain of Influenza A.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H1N1 - PCR negative, cell culture negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H1N1 - PCR negative, cell culture positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H1N1 - PCR positive, cell culture negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H1N1 - PCR positive, cell culture positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2 - PCR negative, cell culture negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2 - PCR negative, cell culture positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2 - PCR positive, cell culture negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2 - PCR positive, cell culture positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Maternal Participants With Season-specific LAIV Influenza A and B Strains Detected in Breast Milk Following Vaccination.</title>
        <description>Breast milk was collected from all maternal participants prior at Days 2 and 8 post vaccination for PCR and cell culture to assess for the presence of the viruses in the LAIV vaccine. The data coordinating center selected 25% of participants in the TIV group for testing to serve as an internal control for the assay.</description>
        <time_frame>Day 2 and 8 post vaccination</time_frame>
        <population>All participants with samples selected for testing by the data coordinating center, 100% of LAIV recipients and 25% of TIV recipients, are included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Maternal LAIV 2011-2012</title>
            <description>Healthy women who planned to breast feed through 28 days post vaccination received 0.2 mL of licensed live attenuated influenza vaccine (LAIV), Flumist®, intranasally in the 2011-2012 season</description>
          </group>
          <group group_id="O2">
            <title>Maternal LAIV 2012-2013</title>
            <description>Healthy women who planned to breast feed through 28 days post vaccination received 0.2 mL of licensed live attenuated influenza vaccine (LAIV), Flumist®, intranasally in the 2012-2013 season</description>
          </group>
          <group group_id="O3">
            <title>Maternal TIV 2011-2012</title>
            <description>Healthy women who planned to breast feed for 28 days post vaccination received 0.5 mL licensed seasonal trivalent influenza vaccine (TIV) by intramuscular injection, Fluzone®, by intramuscular injection in the 2011-2012 season</description>
          </group>
          <group group_id="O4">
            <title>Maternal TIV 2012-2013</title>
            <description>Healthy women who planned to breast feed for 28 days post vaccination received 0.5 mL licensed seasonal trivalent influenza vaccine (TIV) by intramuscular injection, Fluzone®, by intramuscular injection in the 2012-2013 season</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Maternal Participants With Season-specific LAIV Influenza A and B Strains Detected in Breast Milk Following Vaccination.</title>
          <description>Breast milk was collected from all maternal participants prior at Days 2 and 8 post vaccination for PCR and cell culture to assess for the presence of the viruses in the LAIV vaccine. The data coordinating center selected 25% of participants in the TIV group for testing to serve as an internal control for the assay.</description>
          <population>All participants with samples selected for testing by the data coordinating center, 100% of LAIV recipients and 25% of TIV recipients, are included in the analysis.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="47"/>
                <count group_id="O3" value="19"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 2 - Influenza A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8 - Influenza A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2- Influenza B</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8 - Influenza B</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ELISA IgA and IgG GMT to Each of the Influenza Strains in the Vaccine Received in Sera of Maternal Subjects</title>
        <description>Blood was collected from maternal subjects on Day 0 prior to vaccination, and at Day 28 post vaccination for assessment of IgA and IgG antibodies with a standard ELISA assay. The ELISA assay was conducted with the antigens in the 2011-2012 seasonal influenza vaccine, A/Perth/16/2009 (H3N2) and B/Brisbane/60/2008, those in the 2012-2013 seasonal influenza vaccine, A/Victoria/361/2011 and B/Wisconsin/1/2010, and the antigen in both seasons' vaccines, A/California/7/2009 (H1N1). The lower limit of detection is 5.82 units/mL for IgA and 2.56 units/mL for IgG. Titers below the limit of detection were reported as one-half the limit of detection.</description>
        <time_frame>Day 0 and Day 28 post vaccination</time_frame>
        <population>All enrolled maternal participants with results reported are included in this analysis population.</population>
        <group_list>
          <group group_id="O1">
            <title>Maternal LAIV 2011-2012</title>
            <description>Healthy women who planned to breast feed through 28 days post vaccination received 0.2 mL of licensed live attenuated influenza vaccine (LAIV), Flumist®, intranasally in the 2011-2012 season</description>
          </group>
          <group group_id="O2">
            <title>Maternal LAIV 2012-2013</title>
            <description>Healthy women who planned to breast feed through 28 days post vaccination received 0.2 mL of licensed live attenuated influenza vaccine (LAIV), Flumist®, intranasally in the 2012-2013 season</description>
          </group>
          <group group_id="O3">
            <title>Maternal TIV 2011-2012</title>
            <description>Healthy women who planned to breast feed for 28 days post vaccination received 0.5 mL licensed seasonal trivalent influenza vaccine (TIV) by intramuscular injection, Fluzone®, by intramuscular injection in the 2011-2012 season</description>
          </group>
          <group group_id="O4">
            <title>Maternal TIV 2012-2013</title>
            <description>Healthy women who planned to breast feed for 28 days post vaccination received 0.5 mL licensed seasonal trivalent influenza vaccine (TIV) by intramuscular injection, Fluzone®, by intramuscular injection in the 2012-2013 season</description>
          </group>
        </group_list>
        <measure>
          <title>ELISA IgA and IgG GMT to Each of the Influenza Strains in the Vaccine Received in Sera of Maternal Subjects</title>
          <description>Blood was collected from maternal subjects on Day 0 prior to vaccination, and at Day 28 post vaccination for assessment of IgA and IgG antibodies with a standard ELISA assay. The ELISA assay was conducted with the antigens in the 2011-2012 seasonal influenza vaccine, A/Perth/16/2009 (H3N2) and B/Brisbane/60/2008, those in the 2012-2013 seasonal influenza vaccine, A/Victoria/361/2011 and B/Wisconsin/1/2010, and the antigen in both seasons' vaccines, A/California/7/2009 (H1N1). The lower limit of detection is 5.82 units/mL for IgA and 2.56 units/mL for IgG. Titers below the limit of detection were reported as one-half the limit of detection.</description>
          <population>All enrolled maternal participants with results reported are included in this analysis population.</population>
          <units>units/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
                <count group_id="O2" value="48"/>
                <count group_id="O3" value="74"/>
                <count group_id="O4" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 0 IgA to A/California/7/2009 (H1N1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="180.3" lower_limit="132.2" upper_limit="245.9"/>
                    <measurement group_id="O2" value="248.8" lower_limit="163.4" upper_limit="378.6"/>
                    <measurement group_id="O3" value="220.0" lower_limit="156.6" upper_limit="309.2"/>
                    <measurement group_id="O4" value="212.9" lower_limit="140.7" upper_limit="322.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28 IgA to A/California/7/2009 (H1N1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="211.0" lower_limit="152.5" upper_limit="291.9"/>
                    <measurement group_id="O2" value="281.0" lower_limit="193.6" upper_limit="407.8"/>
                    <measurement group_id="O3" value="845.3" lower_limit="559.9" upper_limit="1276.2"/>
                    <measurement group_id="O4" value="417.2" lower_limit="273.9" upper_limit="635.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 0 IgA to A/Perth/16/2009 (H3N2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="724.2" lower_limit="527.3" upper_limit="994.6"/>
                    <measurement group_id="O2" value="1065.7" lower_limit="734.4" upper_limit="1546.5"/>
                    <measurement group_id="O3" value="611.2" lower_limit="466.1" upper_limit="801.5"/>
                    <measurement group_id="O4" value="697.7" lower_limit="512.0" upper_limit="950.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28 IgA to A/Perth/16/2009 (H3N2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="949.6" lower_limit="690.2" upper_limit="1306.5"/>
                    <measurement group_id="O2" value="1400.9" lower_limit="1010.8" upper_limit="1941.5"/>
                    <measurement group_id="O3" value="1514.9" lower_limit="1154.3" upper_limit="1988.3"/>
                    <measurement group_id="O4" value="1262.5" lower_limit="913.4" upper_limit="1745.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 0 IgA to A/Victoria/361/2011 (H3N2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="697.7" lower_limit="509.7" upper_limit="955.1"/>
                    <measurement group_id="O2" value="986.4" lower_limit="685.6" upper_limit="1419.2"/>
                    <measurement group_id="O3" value="601.9" lower_limit="457.9" upper_limit="791.1"/>
                    <measurement group_id="O4" value="678.2" lower_limit="491.7" upper_limit="935.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28 IgA to A/Victoria/361/2011 (H3N2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="920.1" lower_limit="669.7" upper_limit="1264.1"/>
                    <measurement group_id="O2" value="1308.8" lower_limit="949.5" upper_limit="1804.0"/>
                    <measurement group_id="O3" value="1455.3" lower_limit="1103.2" upper_limit="1919.6"/>
                    <measurement group_id="O4" value="1206.2" lower_limit="875.5" upper_limit="1661.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 0 IgA to B/Brisbane/60/2008</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="459.4" lower_limit="361.9" upper_limit="583.1"/>
                    <measurement group_id="O2" value="632.6" lower_limit="440.0" upper_limit="909.7"/>
                    <measurement group_id="O3" value="408.3" lower_limit="310.6" upper_limit="536.7"/>
                    <measurement group_id="O4" value="532.1" lower_limit="376.2" upper_limit="752.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28 IgA to B/Brisbane/60/2008</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="637.2" lower_limit="505.9" upper_limit="802.7"/>
                    <measurement group_id="O2" value="745.8" lower_limit="510.8" upper_limit="1089.1"/>
                    <measurement group_id="O3" value="753.0" lower_limit="561.9" upper_limit="1009.2"/>
                    <measurement group_id="O4" value="933.4" lower_limit="648.0" upper_limit="1344.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 0 IgA to B/Wisconsin/1/2010</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="217.5" lower_limit="172.2" upper_limit="274.7"/>
                    <measurement group_id="O2" value="264.9" lower_limit="183.3" upper_limit="382.7"/>
                    <measurement group_id="O3" value="228.3" lower_limit="176.1" upper_limit="295.9"/>
                    <measurement group_id="O4" value="276.4" lower_limit="196.1" upper_limit="389.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28 IgA to B/Wisconsin/1/2010</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="281.3" lower_limit="226.8" upper_limit="348.9"/>
                    <measurement group_id="O2" value="382.0" lower_limit="265.0" upper_limit="550.6"/>
                    <measurement group_id="O3" value="314.1" lower_limit="241.5" upper_limit="408.5"/>
                    <measurement group_id="O4" value="1034.3" lower_limit="625.1" upper_limit="1711.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 0 IgG to A/California/7/2009 (H1N1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1224.8" lower_limit="988.8" upper_limit="1517.1"/>
                    <measurement group_id="O2" value="1014.6" lower_limit="764.2" upper_limit="1347.0"/>
                    <measurement group_id="O3" value="1133.5" lower_limit="876.4" upper_limit="1465.9"/>
                    <measurement group_id="O4" value="1301.6" lower_limit="964.9" upper_limit="1755.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28 IgG to A/California/7/2009 (H1N1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1193.9" lower_limit="963.1" upper_limit="1479.9"/>
                    <measurement group_id="O2" value="1078.9" lower_limit="823.0" upper_limit="1414.5"/>
                    <measurement group_id="O3" value="5834.1" lower_limit="4507.4" upper_limit="7551.4"/>
                    <measurement group_id="O4" value="3526.6" lower_limit="2794.0" upper_limit="4451.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 0 IgG to A/Perth/16/2009 (H3N2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2228.8" lower_limit="1790.2" upper_limit="2774.8"/>
                    <measurement group_id="O2" value="2022.0" lower_limit="1557.9" upper_limit="2624.2"/>
                    <measurement group_id="O3" value="1798.5" lower_limit="1375.6" upper_limit="2351.5"/>
                    <measurement group_id="O4" value="2244.7" lower_limit="1775.8" upper_limit="2837.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28 IgG to A/Perth/16/2009 (H3N2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2389.8" lower_limit="1931.9" upper_limit="2956.2"/>
                    <measurement group_id="O2" value="2296.1" lower_limit="1780.8" upper_limit="2960.4"/>
                    <measurement group_id="O3" value="5594.7" lower_limit="4546.6" upper_limit="6884.5"/>
                    <measurement group_id="O4" value="5655.1" lower_limit="4556.8" upper_limit="7018.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 0 IgG to A/Victoria/361/2011 (H3N2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2496.3" lower_limit="1998.8" upper_limit="3117.7"/>
                    <measurement group_id="O2" value="2065.7" lower_limit="1537.6" upper_limit="2775.2"/>
                    <measurement group_id="O3" value="2018.9" lower_limit="1566.0" upper_limit="2602.8"/>
                    <measurement group_id="O4" value="2242.8" lower_limit="1724.4" upper_limit="2917.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28 IgG to A/Victoria/361/2011 (H3N2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2742.3" lower_limit="2217.6" upper_limit="3391.3"/>
                    <measurement group_id="O2" value="2275.6" lower_limit="1697.7" upper_limit="3050.3"/>
                    <measurement group_id="O3" value="6132.1" lower_limit="4993.7" upper_limit="7530.0"/>
                    <measurement group_id="O4" value="5996.0" lower_limit="4676.6" upper_limit="7687.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 0 IgG to B/Brisbane/60/2008</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2844.8" lower_limit="2240.9" upper_limit="3611.4"/>
                    <measurement group_id="O2" value="2225.8" lower_limit="1630.4" upper_limit="3038.7"/>
                    <measurement group_id="O3" value="2159.5" lower_limit="1716.8" upper_limit="2716.2"/>
                    <measurement group_id="O4" value="2617.4" lower_limit="2069.6" upper_limit="3310.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28 IgG to B/Brisbane/60/2008</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3064.5" lower_limit="2465.3" upper_limit="3809.3"/>
                    <measurement group_id="O2" value="2381.0" lower_limit="1760.7" upper_limit="3219.9"/>
                    <measurement group_id="O3" value="5813.6" lower_limit="4851.7" upper_limit="6966.1"/>
                    <measurement group_id="O4" value="3897.7" lower_limit="3149.6" upper_limit="4823.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 0 IgG to B/Wisconsin/1/2010</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1279.6" lower_limit="988.2" upper_limit="1656.8"/>
                    <measurement group_id="O2" value="919.4" lower_limit="652.0" upper_limit="1296.5"/>
                    <measurement group_id="O3" value="1071.2" lower_limit="840.9" upper_limit="1364.6"/>
                    <measurement group_id="O4" value="1532.9" lower_limit="1146.3" upper_limit="2049.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28 IgG to B/Wisconsin/1/2010</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1337.2" lower_limit="1048.0" upper_limit="1706.4"/>
                    <measurement group_id="O2" value="1185.2" lower_limit="868.5" upper_limit="1617.3"/>
                    <measurement group_id="O3" value="1914.0" lower_limit="1586.3" upper_limit="2309.3"/>
                    <measurement group_id="O4" value="5840.2" lower_limit="4417.0" upper_limit="7722.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Solicited systemic and local symptoms were collected for 8 days after vaccination (maternal), 10 days (infant). Unsolicited AEs were collected for 28 days and SAEs and new onset chronic medical conditions were collected for 6 months after vaccination.</time_frame>
      <desc>For events solicited on the Memory Aid, a participant was considered to have 1 event if it was reported as experienced at any time in the 8 day period for maternal arms, 10 days for infant arms. Number at risk is 0 for infant arms for events solicited only for maternal arms, and 0 for maternal arms for events solicited only for infants.</desc>
      <group_list>
        <group group_id="E1">
          <title>Maternal LAIV</title>
          <description>Healthy women who planned to breast feed through 28 days post vaccination received 0.2 mL of licensed live attenuated influenza vaccine (LAIV), Flumist®, intranasally, and 0.5 ml of sterile saline placebo by intramuscular injection.</description>
        </group>
        <group group_id="E2">
          <title>Maternal TIV</title>
          <description>Healthy women who planned to breast feed for 28 days post vaccination received 0.5 mL licensed seasonal trivalent influenza vaccine (TIV) by intramuscular injection, Fluzone®, by intramuscular injection, and 0.2 mL sucrose phosphate placebo intranasally.</description>
        </group>
        <group group_id="E3">
          <title>Infant LAIV</title>
          <description>Infants of women enrolled to receive LAIV were enrolled separately in the protocol to be followed for safety outcomes.</description>
        </group>
        <group group_id="E4">
          <title>Infant TIV</title>
          <description>Infants of women enrolled to receive TIV were enrolled separately in the protocol to be followed for safety outcomes.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (16.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="124"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="124"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="125"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Congenital syphilis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="124"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="125"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="124"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>Respiratory syncytial virus bronchiolitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="125"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Retained placenta or membranes</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="124"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="125"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (16.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="106" subjects_at_risk="124"/>
                <counts group_id="E2" subjects_affected="122" subjects_at_risk="124"/>
                <counts group_id="E3" subjects_affected="102" subjects_at_risk="124"/>
                <counts group_id="E4" subjects_affected="101" subjects_at_risk="125"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="124"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="124"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Feeling hot</sub_title>
                <description>Solicited as 'feverishness' on the memory aid</description>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="124"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="124"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <description>Solicited at 'fatigue/malaise' on the memory aid</description>
                <counts group_id="E1" events="45" subjects_affected="45" subjects_at_risk="124"/>
                <counts group_id="E2" events="38" subjects_affected="38" subjects_at_risk="124"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="124"/>
                <counts group_id="E2" events="70" subjects_affected="70" subjects_at_risk="124"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Tenderness</sub_title>
                <description>Solicited specifically for at the injection site on the memory aid.</description>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="124"/>
                <counts group_id="E2" events="100" subjects_affected="100" subjects_at_risk="124"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="124"/>
                <counts group_id="E2" events="23" subjects_affected="23" subjects_at_risk="124"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Injection site swelling</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="124"/>
                <counts group_id="E2" events="18" subjects_affected="18" subjects_at_risk="124"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="124"/>
                <counts group_id="E4" events="8" subjects_affected="8" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="124"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="124"/>
                <counts group_id="E3" events="28" subjects_affected="28" subjects_at_risk="124"/>
                <counts group_id="E4" events="23" subjects_affected="23" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <description>Solicited as 'irritability/fussiness' on the memory aid</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="74" subjects_affected="74" subjects_at_risk="124"/>
                <counts group_id="E4" events="56" subjects_affected="56" subjects_at_risk="125"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="124"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="124"/>
                <counts group_id="E3" events="15" subjects_affected="15" subjects_at_risk="124"/>
                <counts group_id="E4" events="10" subjects_affected="10" subjects_at_risk="125"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <description>Solicited as 'loss of appetite' on the memory aid</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="20" subjects_affected="20" subjects_at_risk="124"/>
                <counts group_id="E4" events="14" subjects_affected="14" subjects_at_risk="125"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <description>Solicited as 'generalized body aches/myalgia' on the memory aid</description>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="124"/>
                <counts group_id="E2" events="23" subjects_affected="23" subjects_at_risk="124"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="53" subjects_affected="53" subjects_at_risk="124"/>
                <counts group_id="E2" events="48" subjects_affected="48" subjects_at_risk="124"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <description>Solicited as 'drowsiness' on the memory aid.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="42" subjects_affected="42" subjects_at_risk="124"/>
                <counts group_id="E4" events="33" subjects_affected="33" subjects_at_risk="125"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="56" subjects_affected="56" subjects_at_risk="124"/>
                <counts group_id="E2" events="26" subjects_affected="26" subjects_at_risk="124"/>
                <counts group_id="E3" events="54" subjects_affected="54" subjects_at_risk="124"/>
                <counts group_id="E4" events="54" subjects_affected="54" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <description>Solicited as 'runny nose' on the memory aid</description>
                <counts group_id="E1" events="51" subjects_affected="51" subjects_at_risk="124"/>
                <counts group_id="E2" events="38" subjects_affected="38" subjects_at_risk="124"/>
                <counts group_id="E3" events="18" subjects_affected="18" subjects_at_risk="124"/>
                <counts group_id="E4" events="30" subjects_affected="30" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="124"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="124"/>
                <counts group_id="E3" events="15" subjects_affected="15" subjects_at_risk="124"/>
                <counts group_id="E4" events="18" subjects_affected="18" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <description>Solicited as 'sore throat' on the memory aid</description>
                <counts group_id="E1" events="39" subjects_affected="39" subjects_at_risk="124"/>
                <counts group_id="E2" events="32" subjects_affected="32" subjects_at_risk="124"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="124"/>
                <counts group_id="E4" events="7" subjects_affected="7" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <description>Solicited as 'difficulty breathing' on the memory aid</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="12" subjects_affected="12" subjects_at_risk="124"/>
                <counts group_id="E4" events="7" subjects_affected="7" subjects_at_risk="125"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Mark Steinhoff, MD</name_or_title>
      <organization>Cincinnati Children’s Hospital Medical Center</organization>
      <phone>513-636-2791</phone>
      <email>Mark.steinhoff@cchmc.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

